Quantification of Fundus Autofluorescence Features in a Molecularly Characterized Cohort of More Than 3000 Inherited Retinal Disease Patients from the United Kingdom

William Woof[1,2*], Thales A. C. de Guimarães[1,2*], Saoud Al-Khuzaei[3*], Malena Daich Varela[1,2*], Sagnik Sen[2,1*], Pallavi Bagga[1,2], Bernardo Mendes[1,2], Mital Shah[1,2], Paula Burke[4], David Parry[4], Siying Lin[1,2], Gunjan Naik[1,2], Biraja Ghoshal[1,2], Bart Liefers[1,8], Dun Jack Fu[1,2], Michalis Georgiou[1,2], Quang Nguyen[1,2], Alan Sousa da Silva[2], Yichen Liu[1], Yu Fujinami-Yokokawa[6], Nathaniel Kabiri[2], Dayyanah Sumodhee[1,2], Praveen Patel[1,2], Jennifer Furman[1], Ismail Moghul[1,2], Juliana Sallum[7], Samantha R. De Silva[3], Birgit Lorenz[5], Frank Holz[5], Kaoru Fujinami[6], Andrew R Webster[1,2], Omar Mahroo[1,2], Susan M. Downes[3], Savita Madhusuhan[4], Konstantinos Balaskas[1,2*], Michel Michaelides[1,2*], Nikolas Pontikos[1,2*]

[1] University College London Institute of Ophthalmology, 11-43 Bath Street, London , UK
[2] Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London EC1V 2PD, UK
[3] Oxford Eye Hospital, John Radcliffe Hospital, Oxford OX3 9DU, UK
[4] St Paul's Eye Unit,Liverpool University Hospitals NHS Foundation Trust, Liverpool , UK
[5] Transmit Centre of Translational Ophthalmology % Justus-Liebig-Universtiy Giessen, Germany
[6] Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center
[7] Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Federal University of Sao Paulo
[8] Department of Ophthalmology and Epidemiology, Erasmus MC, Rotterdam, The Netherlands

* Authors contributing equally

Corresponding author: n.pontikos@ucl.ac.uk

Abstract

Purpose: To quantify relevant fundus autofluorescence (FAF) image features cross-sectionally and longitudinally in a large cohort of inherited retinal diseases (IRDs) patients.

Design: Retrospective study of imaging data (55-degree blue-FAF on Heidelberg Spectralis) from patients.

Participants: Patients with a clinical and molecularly confirmed diagnosis of IRD who have undergone FAF 55-degree imaging at Moorfields Eye Hospital (MEH) and the Royal Liverpool Hospital (RLH) between 2004 and 2019.

Methods: Five FAF features of interest were defined: vessels, optic disc, perimacular ring of increased signal (ring), relative hypo-autofluorescence (hypo-AF) and hyper-autofluorescence (hyper-AF). Features were manually annotated by six graders in a subset of patients based on a defined grading protocol to produce segmentation masks to train an AI model, AIRDetect, which was then applied to the entire imaging dataset.

Main Outcome Measures: Quantitative FAF imaging features including area in mm^2 and vessel metrics, were analysed cross-sectionally by gene and age, and longitudinally to determine rate of progression. AIRDetect feature segmentation and detection were validated with Dice score and precision/recall, respectively.

Results: A total of 45,749 FAF images from 3,606 IRD patients from MEH covering 170 genes were automatically segmented using AIRDetect. Model-grader Dice scores for disc, hypo-AF, hyper-AF, ring and vessels were respectively 0.86, 0.72, 0.69, 0.68 and 0.65. The five genes with the largest hypo-AF areas were *CHM*, *ABCC6*, *ABCA4*, *RDH12*, and *RPE65*, with mean per-patient areas of 41.5, 30.0, 21.9, 21.4, and 15.1 mm^2. The five genes with the largest hyper-AF areas were *BEST1*, *CDH23*, *RDH12*, *MYO7A*, and *NR2E3*, with mean areas of 0.49, 0.45, 0.44, 0.39, and 0.34 mm^2 respectively. The five genes with largest ring areas were *CDH23*, *NR2E3*, *CRX*, *EYS* and *MYO7A*, with mean areas of 3.63, 3.32, 2.84, 2.39, and 2.16 mm^2. Vessel density was found to be highest in *EFEMP1*, *BEST1*, *TIMP3*, *RS1*, and *PRPH2* (10.6%, 10.3%, 9.8%, 9.7%, 8.9%) and was lower in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis genes. Longitudinal analysis of decreasing ring area in four RP genes (*RPGR, USH2A, RHO, EYS*) found *EYS* to be the fastest progressor at -0.18 mm^2/year.

Conclusions: We have conducted the first large-scale cross-sectional and longitudinal quantitative analysis of FAF features across a diverse range of IRDs using a novel AI approach.

Introduction

Inherited retinal diseases (IRDs) are clinically and genetically heterogeneous disorders that affect the retina, and represent the leading cause of certifiable blindness among working-age adults in England and Wales and the second commonest cause in childhood [1]. This group of disorders can be caused by genetic mutations in any one of over 270 genes [2-4].

Many IRDs are associated with structural changes within the retina, which can be detected with retinal imaging using different imaging modalities such as colour fundus, infrared-reflectance (IR), spectral-domain optical coherence tomography (SD-OCT), or fundus autofluorescence (FAF). FAF is of particular importance in the context of IRDs, as it allows the detection of patterns of fluorophores, often at the level of the photoreceptors and retinal pigment epithelium (RPE), which can be indicative of pathological changes such as loss of overlying photoreceptors [5,6]. Some of these FAF signal changes are highly characteristic of specific IRDs and can indicate features such as areas of RPE atrophy or lipofuscin deposits. FAF is listed as a primary or secondary outcome in multiple clinical trials, and it has become a useful retinal biomarker for diagnostic and prognostication purposes in a wide variety of IRDs [3,7,8].

The identification and quantification of features of degeneration within retinal imaging is critical for diagnosis, monitoring disease progression, providing prognostic information and assessing treatments in IRDs. The first steps in quantifying retinal imaging-based biomarkers of disease involves identification and segmentation of these features. Manual segmentation performed by human annotators is time consuming and requires expert annotators, which makes this process subjective and not feasible on a large scale. Automated identification and segmentation of IRD features in a reliable way is important for enabling the routine use of these data quantitatively in clinical practice and to help further our understanding of these diseases.

Existing studies that have used deep learning to segment IRD features from retinal images have so far focused on specific IRD phenotypes such as retinitis pigmentosa (RP), Stargardt (STGD1), and choroideremia (CHM) [9,10].

To support our analysis on a broad range of different IRD phenotypes, we develop AIRDetect, a deep learning model that can automatically identify and segment relevant features from FAF images. We apply AIRDetect to the entire cohort of IRD patients with molecularly confirmed diagnoses at Moorfields Eye Hospital, to identify gene-phenotype associations, as well as quantify disease progression.

Methods

Dataset Curation

Patients' genotypes were extracted from the Genetics database of Moorfields Eye Hospital

(MEH, London, UK) [2,11]. Patients' images were exported from the Heidelberg Imaging

(Heyex) database (Heidelberg Engineering, Heidelberg, Germany) based on their hospital

number, for records between 2004-06-17 and 2019-10-22. All 55-degree FAF images were

488nm blue-FAF images captured by the Heidelberg Spectralis imaging platform.

A dataset of 736 blue-FAF images (55-degree) from 573 patients from MEH were annotated

with four different image features, optic disc, regions of hyper- and hypo-autofluorescence

(AF), and perimacular ring of increased signal, and a further set of 206 blue-FAF images

(55-degree) from 127 patients from the Royal Liverpool Hospital (RLH) were annotated with

the retina vessel tree. A grading protocol was defined for IRD retinal feature annotations

(**Table 1**) [12]. The Dice similarity coefficient score was used to assess inter-grader agreement

[13]. Manual grading was completed over an 18-month period from June 2022 to December

2023 by four graders, with two additional graders carrying out the vessel segmentation at

RLH. Manual grading was performed using the Moorfields Grading Portal online platform

(grading.readingcentre.org). A full breakdown of the manually annotated dataset is given in

Supplementary Table 1.

Name	Shorthand	Includes	Excludes
Optic Disc	disc	The optic nerve head. Includes both the optic cup and rim.	Peripapillary atrophy not included in annotation.
Hypo-autofluorescence	hypo-AF	Areas distinctly darker than physiological normal area with 50% grader confidence. The level of hypo-AF should be at least 90-100% as dark as the optic disc. Note this is relative AF rather than absolute AF.	Excludes peripapillary atrophy. Areas of ambiguous (not definitely decreased) regions in the periphery are not annotated as hypo-AF.
Hyper-autofluorescence	hyper-AF	Regions brighter than physiological normal area with 50% grader confidence. Note this is relative AF rather than absolute AF.	Excludes macular ring. Excludes flecks.
Perimacular ring of increased signal	ring	Ring shaped area of hyper-AF within the vascular arcades at the macula.	Must be >50% complete circle.
Veins and Arteries	vessels	All visible retinal vessels stemming from the optic disc.	Only annotated over atrophy if the grader is more than 50% certain of the location of the vessel.

126 **Table 1**: Features and definitions used during the annotation process of five features by the graders.

Training and Test Datasets

The annotated dataset was compiled, and any images without confirmation for all features

from at least one grader at the time of model development were discarded, and, to avoid

bias, the annotation from a single grader was randomly selected where grader annotations

were available for a single image. After this process there were 554 images from 464

patients from MEH. The MEH training set consisted of 506 images from 424 patients from.

The MEH hold-out test set consisted of 48 images from 40 patients. The RLH training set

consisted of 72 images from 52 patients from RLH. The RLH hold-out test set consisted of

23 images from 22 patients. Training sets were split into five separate sets for use with 5-fold

cross validation, ensuring a balanced representation of each class across folds. Assignment

to the training and test sets was done at patient-level to avoid any potential data leakage.

The data flowchart is fully described in **Supplementary Figure 1**.

Development of AIRDetect Segmentation Model

For training the AIRDetect segmentation model, we selected the nnU-Net (no-new-UNet)

framework for its adaptability and performance in automatic medical image segmentation

tasks [14]. At its core, nnU-Net leverages a fully convolutional network design inspired by the

U-Net architecture, renowned for its efficacy in medical imaging tasks [15–17]. The overlying

nnU-Net framework then automatically configures its network architecture, preprocessing,

and training strategy based on the dataset's characteristics, optimising for performance,

without requiring manual hyperparameter tuning or architecture modifications from the user.

For the five different image features, we trained two separate nnU-net models. A single

multi-class model for disc, hyper-AF and hypo-AF, and ring, and a separate single-class

model for vessels. As with common practice for nn-Unet each model consisted of an

ensemble of five U-nets with identical architectures, but different weights, trained

independently and then ensembled at inference, taking the unweighted average of the

probability scores across networks.

The model was trained using a sum of Dice and cross-entropy loss functions to optimise for

multi-class segmentation accuracy. Hyperparameters, such as learning rate and batch size,

were selected by the nnU-Net based on its analysis of the dataset. Training was curtailed at

200 epochs as this was sufficient to achieve convergence in most cases.

163 Validation of AIRDetect Segmentation Model

Model validation was assessed using the Dice coefficient between the model predictions and

the corresponding grader annotation on the hold-out test set. Where images were double

graded, we took the mean of the model-grader Dice for each grading. We also analysed the

accuracy of the model-grader agreement for simple presence/absence detection where we

counted cases as positive for which the model/annotator marked at least some part of the

image for the given feature, and negative otherwise, from which we derived

presence/absence detection accuracy, precision and recall.

171 Automatic Annotations on Real World IRD Dataset

The trained models were applied to automatically segment 45,749 FAF images (55-degree)

from 3,606 IRD patients with a molecularly confirmed diagnosis from MEH covering 170

genes [2,11]. Images where the optic disc was not segmented by the model were removed, as

these images were of poor quality or not centred on the macula (**Supplementary Figure 2**).

Results were analysed from 33,042 FAF images from 3,496 patients, after filtering.

For each of the generated masks we extracted: a) if the feature was present or absent; b)

the area, number of pixels in the segmented mask multiplied by the resolution; c) the number

of connected components, found using watershed clustering [18]; d) feature brightness, mean

intensity of pixels from the region covered by the segmented mask. For vessels, we

calculated a selection of metrics defined in **Supplementary Table 2**, using the provided

code from the reti-py library as used in the AutoMorph repository [19]. Features were also

analysed based on their distance from the fovea.

To calculate rate of progression for a given feature, a linear regression was fit to each

patient-eye, taking time since the first appointment (in years) as the independent variable,

and taking the calculated areas of the segmented feature at each time-point as the

measured variable. The slope of the regression was then averaged across eyes per-patient

to give a rate of progression. Where multiple scans per eye were present for a given date,

we took the most recent scan with the rationale that good quality scans were less likely to

lead to further imaging by the operator.

194 Results

195 AIRDetect Model Validation

Examples of AIRDetect segmentation output are presented in **Figure 1**. Model-grader Dice

scores for disc, hypo-AF, hyper-AF, ring and vessels were respectively 0.86, 0.72, 0.69, 0.68

and 0.65, with intergrader Dice scores of 0.82, 0.75, 0.72, 0.80, 0.95, respectively. Model

detection accuracy ranged from 77% to 83% (excluding anatomical features) (**Table 2)**.

Features which were the most challenging to detect were hyper-AF and ring as those had

the lowest precision scores at 0.53 and 0.60 respectively.

Figure 1: Examples of manually and automatically segmented masks for the five features: vessels,
disc, ring, hyper- and hypo-autofluorescence. The vessel dataset was separate to the rest of the data,
so vessel visualisation is separate from other features.
206
207
208

	Train set		Test Set		Segmentation (Dice)		Detection (Presence/Absence)		
Feature	Total	Incidence	Total	Incidence	Inter-grader	Model-grader	Accuracy	Precision	Recall
disc	506	98%	48	98%	0.82	0.86	-	-	-
hypo-AF	506	70%	48	44%	0.75	0.72	83.3%	0.81	0.81
hyper-AF	506	18%	48	23%	0.72	0.69	79.2%	0.53	0.82
ring	506	32%	48	31%	0.80	0.68	77.1%	0.60	0.80
vessels	72	100%	23	100%	0.94	0.65	-	-	-

Gene-phenotype Associations

Analysing associations between identified features and genes across most common genes
(**Supplementary Table 3**), the five genes with the largest hypo-AF areas were *CHM*,
ABCC6, *ABCA4*, *RDH12*, and *RPE65*, with mean per-patient areas of 41.5, 30.0, 21.9, 21.4,
and 15.1 mm^2 (**Figure 2a)**. The five genes with the largest hyper-AF areas were *BEST1*,
CDH23, *RDH12*, *MYO7A*, and *NR2E3*, with mean areas of 0.49, 0.45, 0.44, 0.39, and 0.34
mm^2 respectively (**Figure 2b**). The five genes with largest ring areas were *CDH23*, *NR2E3*,
CRX, *EYS* and *MYO7A,* with mean areas of 3.63, 3.32, 2.84, 2.39, and 2.16 mm^2 (**Figure
2c**). At the gene variant level, considering the p.(Gly1961Glu) ABCA4 variant showed a
higher ring area than the other common *ABCA4* variants (**Supplementary Figure 4).** Vessel
density was found to be highest in *EFEMP1*, *BEST1*, *TIMP3*, *RS1*, and *PRPH2* (10.6%,
10.3%, 9.8%, 9.7%, 8.9%) and was lower in Retinitis Pigmentosa (RP) and Leber Congenital
Amaurosis associated genes (**Figure 2d).** A full breakdown of features across the 30 most
common genes is given in **Supplementary Table 3**, for all genes in **Supplementary Table
4** and for vessels in **Supplementary Table 5**.

Figure 2: Mean **a)** extent of hypo-AF, **b)** extent of hyper-AF, **c)** extent of ring, and, **d)** Vessel density (ratio between area of vessels and total image area) across the 30 most common genes (*RPE65* included for reference). Error bars denote standard error. Values were first averaged by patient before averaging by gene to minimise correlations due to multiple contributions from individual patients. Genes are grouped into approximate phenotype groupings denoted by bar styling.

We analysed how features vary with distance from the fovea by looking at the prevalence of each feature in each 0.5 mm annulus moving away from the fovea. **Figure 3** compares prevalence of hyper- and hypo-AF at different distances from the fovea in five different genes (see **Supplementary Figure 7** for scale). The two genes associated largely with maculopathy or cone-rod dystrophy (*ABCA4*, *PRPH2*) show increased hypo-AF at the fovea (**Figure 3.a** and **Figure 2.a**) but reducing proportions of the retina displaying hypo-AF moving away from the fovea. The two RP associated genes (*USH2A*, *RPGR*) show less hypo-AF across the whole retina compared with the cone-rod genes, but with a bimodal profile, with the greatest relative proportion of hypo-AF at the fovea followed by 4-6mm from the fovea, just within the vascular arcade. For *CHM*, unlike the other genes, there was the least hypo-AF at the fovea, but substantially increased hypo-AF away from the fovea. For hyper-AF there is an increased proportion of hyper-AF at the fovea in all genes except *ABCA4* that reduces further from the fovea (**Figure 3b**). In the two RP associated genes (*USH2A, RPGR*) there is an increase in hyper-AF at 1-3mm from the fovea.

Figure 3: Autofluorescence (AF) as a proportion of total altered AF area in the image compared with distance from fovea for patients with variants in *ABCA4*, *RPGR*, *USH2A*, *RPGR*, and *CHM* for **a)** hypo-AF and **b)** hyper-AF.

In **Figure 4** the area of hyper-AF within 1.5mm of the fovea is compared against patient age for five different IRD genes. Most genes showed an increase with age, with the exception of *PRPH2*, which remained fairly stationary, and *BEST1*, which demonstrated a sharp decrease with patient age - although there was a considerable variability across ages within all genes.

Figure 4: hyper-AF area within 1.5mm of the fovea (corresponding to inner 3mm ETDRs ring) compared with patient age. Least-squares regression line in red. Significant increase in hyper-AF with age for *ABCA4* (β=691 µm^2/yr, p<0.001), *USH2A* (β=4090µm^2/yr, p<0.001) and *RPGR* (β=2520µm^2/yr, p<0.029). Significant decrease for *BEST1* (β=-6500µm^2/yr, p<0.001). No significant changes of hyper-AF with age were found for *PRPH2*.

.

Disease Progression

We applied AIRDetect longitudinally to monitor progression within individual patients across
multiple visits. **Figure 5** shows an example using AIRDetect to visualise the decrease in ring
area in individual patients with RP associated with variants in four different genes, namely
USH2A, *PRPH2*, *RHO* and *EYS*. Comparing these four RP genes in the entire MEH IRD
cohort, average rate of decrease in total ring area was greater in patients with RP associated
with *EYS* (-0.178 mm^2/year), *USH2A* (-0.066 mm^2/year), and *RPGR* (-0.046 mm^2/year), when
compared to *RHO* (-0.040 mm^2/year).

We also applied AIRDetect to monitor progression in patients belonging to three subgroups
of *ABCA4* (**Figure 6**). Patients were classified into three groups (A, B and C) based on
increasing severity of genetic variants as defined by Cornelis et al. [20,21]. Patients in group A
had two severe variants, while group C had a mild variant in trans with any other variant.
Patients with variants of known severity whose combination do not fit the other two groups
were placed into group B. The average increase in hypo-AF area per year was compared
between groups (**Supplementary Figure 3**). In keeping with previous studies [22–26], the mean
per-patient rate of increase in hypo-AF area was highest in the highest severity classification
(group A), at 3.11 mm^2/year, followed by 1.59 mm^2/year for the intermediate severity group
(B), and finally 0.87 mm^2/year in the lowest severity group (C) (**Supplementary Table 6**)**.**

297
298 **Figure 5**: Automatic monitoring of lesion size for disease progression. Decreasing area of ring for four
299 patients with disease-causing variants in: a) *RPGR*, b) *USH2A*, c) *RHO*, and d) *EYS*. In these genes,
300 the macular ring is expected to shrink in diameter over time as the disease progresses.
301

302
303 **Figure 6:** Increasing area of hypo-AF for two patients of each of the three *ABCA4* severity groups: a)
304 group A, b) group B and c) group C. Here we see the expected patterns of progression reported in
305 **Supplementary Table 6** with A being the fast progressors, followed by B and C.

Discussion

The results of our cross-sectional analysis match known genotype-phenotype associations demonstrating the validity of our approach, as well yielding novel insights. For example in **Figure 2.a**, *CHM* and *ABCA4* both exhibited higher levels of hypo-AF, consistent with the large areas of atrophy that spare the fovea in choroideremia, as well as the macular atrophy typically seen in STGD1 disease (*ABCA4*) [7,27–29]. Of interest however, *ABCC6* which is associated with pseudoxanthoma elasticum was identified to have second largest areas of hypo-AF. On further inspection, can be explained by the large angioid streaks characteristic of this condition which can appear as hypo-AF on FAF[30]. For hyper-AF, *BEST1* exhibited the largest areas of hyper-AF, which can be attributed to the vitelliform lesion(s) that are characteristically observed in autosomal dominant and recessive forms of the disease [31–33] (**Figure 2.b**). For ring the presence of a macular ring typically corresponds to a demarcation between diseased and non-diseased retina, and is usually seen in RP and cone rod dystrophies, in keeping with our findings herein [3] (**Figure 2.c**). The lower vessel density observed in RP and LCA genes was also in keeping with the vessel attenuation commonly associated with these genes[34,35] (**Figure 2.d**). As well as gene-phenotype associations, we also found associations at the individual variant level confirming known association between the p.(Gly1961Glu) variant in *ABCA4* and presence of a macular ring [36–39] (**Supplementary Figure 3)**. When considering feature prevalence from the fovea, we found, as expected, that genes usually associated with cone-rod degeneration showed a decrease in hypo-AF extent moving away from the fovea, but with an opposite trend for the RP genes and *CHM* (**Figure 3)**. Hyper-AF was mainly concentrated at the fovea, but with a distinctive peak at 2-3mm from the fovea which may be attributed to partial macular rings classified as hyper-AF by our model (**Figure 3.b**). *PRPH2* also had a higher coverage of hyper-AF in the fovea when compared to *ABCA4* which is consistent with the pattern/macular dystrophy and adult vitelliform phenotypes associated with *PRPH2* [40] (**Figure 3.b**).

In our longitudinal analysis we were able to replicate the findings of Fakin *et al.* 2016 in **Figure 7** and **Table 4**, where we found that growth of areas of hypo-AF was much more rapid in the group associated with more severe *ABCA4* genetic variants [22]. Our estimates for rate of progression were higher than that previously reported, which may be due to the use of 55-degree as opposed to 30-degree imaging in our dataset and hence a larger area of hypo-AF [25,41]. Comparing hyper-AF across patient age in **Figure 4**, the hyper-AF within 1.5mm of the fovea increased for *ABCA4*, *USH2A* and *RPGR*, consistent with lesions developing with disease progression over time. However, there were some noteworthy exceptions for individual genes. In particular, *BEST1* is associated with "yolk-like" regions of hyper-AF, typically within 2-3mm of the perifovea, which change over time through pre-

vitelliform, vitelliform, pseudohypopyon, vitelliruptive stages and finally to the atrophic stage

[3,33]. The highest hyper-AF signal would be associated with the vitelliform stage, progressively

reducing in intensity to become a region of hypo-AF by the atrophic stage, which matches

what we see as a decrease in foveal hyper-AF with age. No significant progression of

hyper-AF with age was detected for *PRPH2* which is likely due to the later onset of the

condition in most patients (typically after 45 years of age) and hence the limited age range in

our cohort , as well as the milder pattern of dystrophy [42]

We also identified increased rate of decrease in area of macular ring in *EYS, USH2A* and

RPGR compared to *RHO* (**Figure 6**). Monitoring the rate in which the macular ring narrows

down is common practice in generalised retinal dystrophies such as RP [5]. A more rapid

encroachment of the macular ring in autosomal recessive (*USH2A*, *EYS*) and X-linked

(*RPGR*) genes compared to the autosomal dominant *RHO*, is consistent with the latter

having a slower disease progression compared to the others [43].

To date, deep learning AI models to analyse FAF images from IRD patients have been

limited. There have been studies developing classification models of FAF images based on

IRD phenotypes [44–47]. But as to segmentation approaches, areas of hypo-AF have been

measured either manually or semi-automatically using RegionFinder on HEYEX2 software

to study the progression rate of the area of atrophy in STGD1 disease [48–51]. These

approaches compared to deep-learning approaches would be challenging to scale

accurately to our real-world dataset as they require considerable parameter tuning compared

to deep-learning based approaches such as AIRDetect. Previous deep-learning based

segmentation approaches have mostly focused on STGD1 to segment for hypo-AF[52] or

flecks[10]. Hence our AIRDetect approach represents the first to be developed and applied to

a wide range of IRDs covering 170 genes.

One limitation of our approach is that the gene associations described in our study are

limited by the variation in phenotypes which can occur with different variants in the same

gene or different modes of inheritance. For example, *CRX* can be associated with a mild

CORD but also quite severe LCA [53–55]. *RPGR* can be associated with RP, LCA, macular

dystrophy and CORD [56,57]. We conducted a sub analysis in *ABCA4* (**Supplementary Figure**

4) but have not yet conducted this analysis across all gene variants and modes of

inheritance.

Another limitation is the large variance in imaging quality in our real-world dataset, which

affects the reliability of some of the features in lower quality images. While automatic image

quality assessment tools exist for colour fundus retinal imaging [58], none have been

developed for FAF imaging. Assessing image quality can also be particularly challenging for

IRDs as they are associated with a wide range of pathologies, many of which can affect

perceived image quality, as well as make it more challenging for the operator to acquire

good quality images. We plan to develop an IRD FAF image quality assessment model in

future, which should help to improve the consistency of our segmented masks and reduce

noise in our analysis.

We anticipate that AIRDetect can be used to validate further clinically relevant findings, as

well as identifying new potential associations between different feature patterns and certain

genes or variants. Our approach could also be applied to identifying structure-function

association **(Supplementary Figure 5)** as well as cross-modality image registration tasks by

using vessel-based segmentation to align images (**Supplementary Figure 6**). Besides

IRDs, the diverse nature of IRD-associated pathologies might make AIRDetect useful to

improve robustness for segmentation of FAF imaging for other non-IRD conditions or provide

a good starting point for developing models for specific conditions where data is more scarce

or to other imaging modalities such as ultra-widefield imaging, via transfer learning.

In conclusion, we have conducted, to our knowledge, the largest quantitative cross-sectional

and longitudinal analysis of FAF features across a diverse range of IRDs in a real world

dataset, enabled by our novel automatic segmentation AI model, AIRDetect.

401 Ethics

402   This research was approved by the IRB and the UK Health Research Authority Research

403   Ethics Committee (REC) reference (22/WA/0049) "Eye2Gene: accelerating the diagnosis of

404   inherited retinal diseases" Integrated Research Application System (IRAS) (project ID:

405   242050). All research adhered to the tenets of the Declaration of Helsinki.

407 Code availability

The source code for the AIRDetect model architecture training and inference is available

from https://github.com/Eye2Gene/. The model weights of AIRDetect are intellectual

proprietary of UCLB so cannot be shared publicly. However, they may be shared via a

licensing agreement with UCLB. A running version of the AIRDetect app is accessible via the

Eye2Gene website (www.eye2gene.com) and via the Moorfields Grading Portal

(grading.readingcentre.org) on invitation.

Data availability

The data that support the findings of this study are divided into two groups, published data and restricted data. Published data are available from the Github repository. Restricted data are curated for AIRDetect users under a license and cannot be published, to protect patient privacy and intellectual property. Synthetic data derived from the test data has been made available at https://github.com/Eye2Gene/.

Author contributions

WAW analysed the data and wrote the manuscript. NP designed the obtained the funding, designed the experiments, analysed data and wrote the manuscript. MM, KB, WAW, TACG, SAK, MDV, BM designed the experiments, analysed data and wrote the manuscript. SS analysed the data. MS wrote the manuscript. PBa analysed the data. PBu, DP analysed the data. All authors have critically reviewed the manuscript.

Acknowledgement

This work is primarily funded by a NIHR AI Award (AI_AWARD02488) which supported NP, WAW, MM, KB, SD and SM. The research was also supported by a grant from the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. NP was also previously funded by Moorfields Eye Charity Career Development Award (R190031A). BJ was partially funded by IIR-DE-002818 from Shire/Takeda and by the European Reference Network for Rare Malformation Syndromes, Intellectual and Other Neurodevelopmental Disorders (ERN-ITHACA). OAM is supported by the Wellcome Trust (206619/Z/17/Z). AYL is supported by an unrestricted and career development award from RPB, Latham Vision Science Awards, NIH OT2OD032644, NEI/NIH K23EY029246, and NIA/NIH U19AG066567. SA is supported by a scholarship from Qatar National Research Fund (GSRA6-1-0329-19010).This project was also supported by a generous donation by Stephen and Elizabeth Archer in memory of Marion Woods. The hardware used for analysis was supported by the BRC Challenge Fund (BRC3_027). We also gratefully acknowledge the support of NVIDIA Corporation with the donation of the Titan Xp GPU used for this research. The views expressed are those of the authors and not the funding organisations.

Supplementary

Supplementary Figure 1: Data flowchart with number of images, patients, eyes, and genes at each stage of AIRDetect model development.

452   **Supplementary Figure 2**: Examples of images with no Disc segmentation from the model. These are
453   either poor quality, have significant atrophy, or are improperly centred.
454

455
456

457 **Supplementary Table 1:** Overview of annotated dataset for the manually segmented features,
458 considering each feature individually. Not all features were gradable within all images, with some
459 images only annotated for some features. Images for vessel annotations were selected by clinicians
460 and were all gradable. Incidence includes ungradable

Feature	Graded	Double graded	Partially Gradable	Un-Gradable	Num Patients	Num Genes	Present	Incidence
disc	736	207	74	32	573	63	716	97.3%
hypo-AF	736	204	75	32	573	63	482	65.5%
hyper-AF	730	191	77	32	570	63	106	14.5%
ring	729	195	76	32	571	63	212	29.1%
vessels	206	13	n/a	n/a	127	33	206	100%

461
462
463 **Supplementary Table 2:** Vessel metrics and their description.

Vessel Metric	Description
Fractal Dimension	Method that represents geometric complexity of the vascular branching pattern observed in the retina. Essentially how close are the vessels to being "space-filling".
Vessel Density	Ratio between area of vessels and total image area.
Average Width	Average width of vessels.
Distance Tortuosity	Distance tortuosity is a measure of the tortuosity of a path based on the ratio of the actual path length to the straight-line distance between the start and end points of the path [59]
Squared Curvature Tortuosity	Squared curvature tortuosity is a more sophisticated measure of tortuosity that takes into account the curvature along the path, providing a detailed view of its winding nature [59]
Tortuosity Density	Assesses vessel tortuosity by aggregating local contributions, examining the degree to which each turn curve deviates from a smooth curve [60]

464
465   .

Supplementary Table 3: Feature statistics by gene for selected genes. Results are mean across all images. %=Incidence, A=Average Area (mm^2), C=Num Components, I = Intensity (pixel brightness), <3mm=Proportion of feature area within 3mm of the fovea (corresponding to outer 6mm ETRDS ring), D=vessel density, F=fractal dimension. The table cells have been shaded with lower values in red, intermediate values in white and larger values in green.

Gene	disc				hypo-AF					hyper-AF					ring					vessels	
	A	C	I	<3mm	%	A	C	I	<3mm	%	A	C	I	<3mm	%	A	C	I	<3mm	D	F
ABCA4	2.19	1.01	9.20%	13.70%	80.30%	19.81	1.45	11.10%	61.30%	18.00%	0.05	0.33	66.40%	48.30%	33.50%	0.57	1.58	59.60%	81.80%	7.65%	1.33
ABCC6	1.53	1.03	16.90%	17.60%	69.00%	21.44	2.08	14.30%	32.60%	54.90%	0.23	1.2	62.50%	23.40%	8.20%	0.03	0.15	43.30%	38.00%	8.07%	1.37
BBS1	2.59	1.02	10.40%	7.50%	67.50%	8.35	1.29	11.90%	56.90%	25.90%	0.15	0.38	47.30%	86.90%	32.50%	0.84	1.03	56.50%	72.70%	4.56%	1.18
BEST1	1.84	1.01	11.60%	4.10%	40.50%	2.58	0.9	11.50%	59.70%	57.50%	0.73	1.09	61.20%	59.80%	57.50%	1.28	1.83	56.30%	77.20%	9.62%	1.38
CACNA1F	2.04	1.01	14.80%	0.00%	5.70%	0.91	0.2	7.10%	42.40%	12.80%	0.01	0.15	59.80%	2.50%	3.80%	0.01	0.06	53.60%	79.80%	5.35%	1.21
CDH23	2.05	1.01	14.30%	6.40%	16.20%	0.71	0.47	10.40%	42.00%	19.60%	0.23	0.5	57.60%	34.20%	77.30%	2.46	2.73	47.30%	67.30%	2.46%	1.05
CERKL	2.63	1	12.30%	9.10%	82.30%	10.33	1.43	12.10%	51.70%	17.70%	0.02	0.21	46.00%	88.60%	29.70%	1.04	0.95	58.10%	65.30%	3.51%	1.16
CHM	1.45	1.06	20.60%	2.80%	82.60%	51.77	3.28	19.90%	21.00%	48.80%	0.26	0.83	54.50%	37.90%	5.50%	0.03	0.08	43.20%	32.20%	6.20%	1.3
CNGA3	1.74	1.01	13.80%	14.50%	31.10%	1.48	0.96	7.10%	56.30%	8.00%	0.05	0.17	54.00%	31.80%	35.60%	0.32	0.75	50.00%	74.90%	5.36%	1.24
CNGB3	1.91	0.99	14.90%	12.70%	12.50%	0.16	0.38	6.70%	73.60%	10.40%	0.01	0.12	52.70%	63.90%	32.60%	0.2	0.63	54.60%	92.20%	5.92%	1.24
CRB1	1.97	1.02	14.70%	3.60%	55.20%	8.3	1.22	15.60%	40.40%	44.00%	0.41	0.89	46.40%	54.00%	43.70%	1.73	1.35	48.90%	59.20%	4.27%	1.11
CRX	2.11	1	15.60%	5.70%	70.30%	5.51	1.39	15.60%	62.70%	16.90%	0.05	0.26	50.70%	29.90%	59.30%	2.23	4.22	52.90%	65.90%	7.30%	1.33
EFEMP1	1.77	1	15.30%	6.00%	78.70%	5.15	1.84	14.20%	82.40%	77.90%	0.24	1.55	61.80%	79.40%	24.10%	0.18	0.66	60.00%	82.50%	10.10%	1.43
EYS	2.36	1.02	15.20%	2.90%	65.90%	9.55	1.64	13.30%	27.30%	23.40%	0.23	0.4	57.60%	42.90%	72.50%	2.08	2.76	52.60%	76.80%	3.07%	1.16
GUCY2D	2	1	14.70%	6.50%	48.00%	5.25	0.86	17.50%	71.20%	17.60%	0.22	0.3	61.20%	36.00%	60.90%	1.51	2.94	53.10%	75.00%	6.91%	1.29
MYO7A	2.07	0.99	15.80%	2.30%	42.30%	2.37	0.95	18.00%	32.90%	28.00%	0.41	0.97	53.70%	21.80%	73.60%	3.24	3.26	47.00%	57.80%	2.70%	1.09
NR2E3	1.94	1.02	10.90%	7.40%	31.50%	1.42	0.76	10.20%	12.90%	21.40%	0.37	0.5	56.50%	17.90%	39.60%	1.72	1.4	52.20%	24.70%	8.33%	1.32
PDE6B	2.62	1.01	14.80%	3.40%	52.20%	4.48	0.93	17.00%	49.30%	21.30%	0.08	0.28	55.10%	56.90%	86.00%	3.37	4.06	47.30%	86.60%	3.00%	1.12
PROM1	2.3	1.01	12.60%	7.00%	80.00%	12.15	1.72	12.60%	72.00%	21.10%	0.04	0.25	52.30%	72.90%	34.80%	0.85	2.06	54.00%	82.50%	6.10%	1.26
PRPF31	2.2	1.03	15.50%	1.20%	48.10%	6.78	1.56	12.00%	41.30%	18.80%	0.12	0.34	45.90%	68.30%	64.00%	2.17	2.85	52.50%	86.90%	4.10%	1.21
PRPH2	2.05	1.01	12.30%	4.50%	68.70%	10.28	1.89	10.10%	62.00%	36.40%	0.07	0.58	59.10%	77.10%	26.30%	0.69	0.85	55.80%	69.40%	8.00%	1.36
RDH12	1.92	1.01	18.00%	11.80%	58.10%	22.35	1.1	19.00%	37.30%	33.70%	0.37	0.52	49.00%	22.10%	34.10%	1.51	2.52	57.90%	84.80%	2.93%	0.99
RHO	2.17	1.03	15.50%	1.50%	61.90%	9.74	1.72	13.60%	34.80%	18.50%	0.11	0.24	53.00%	56.00%	70.60%	2.25	2.99	53.60%	82.80%	4.47%	1.22
RP1	2.19	1.01	13.70%	5.50%	63.00%	9.32	1.76	13.10%	40.10%	19.10%	0.18	0.27	55.90%	66.70%	65.00%	2.03	2.98	54.60%	74.80%	4.59%	1.23
RP2	2.48	1.05	9.90%	13.30%	47.60%	3.1	1.19	10.50%	48.30%	6.90%	0.02	0.08	54.70%	84.40%	13.00%	0.26	0.38	59.00%	67.80%	3.65%	1.19
RPE65	1.15	1.06	19.30%	7.60%	52.40%	40.13	2.65	15.00%	29.10%	37.80%	0.24	0.65	56.40%	61.80%	4.90%	0.19	0.05	43.10%	97.60%	2.04%	0.97
RPGR	2.31	1.01	13.70%	3.70%	54.20%	7.78	1.27	14.40%	36.50%	22.60%	0.13	0.31	54.40%	58.60%	61.30%	2.13	2.09	55.90%	82.00%	4.06%	1.19
RS1	1.93	1	11.90%	3.50%	26.80%	2.41	0.58	10.70%	36.70%	24.80%	0.1	0.37	44.30%	73.20%	16.90%	0.35	0.59	53.00%	66.40%	8.69%	1.34
TIMP3	1.71	1.01	17.50%	9.50%	62.10%	16.35	1.84	15.30%	46.50%	30.70%	0.14	0.51	58.50%	32.60%	27.00%	0.47	1	55.20%	35.30%	9.15%	1.39
USH2A	2.17	1.02	15.60%	2.30%	61.30%	8.47	1.76	13.00%	36.50%	19.80%	0.15	0.31	53.50%	66.50%	72.10%	1.98	3.2	53.50%	87.50%	3.42%	1.17
All	2.09	1.02	13.50%	6.90%	61.20%	13.04	1.46	13.00%	48.20%	25.10%	0.15	0.43	57.10%	52.80%	43.70%	1.19	1.78	54.10%	77.90%	5.75%	1.25

Supplementary Table 4: Feature statistics for all genes. Phenotypes: pheno = most common phenotype presentation according to literature. ACHM = achromatopsia, ALB = albinism, BEST = best disease, CD = cone-dystrophy, CHM = choroidemia, CR = cone-rod, CSNB = congenital stationary night blindness, DR = diabetic retinopathy, FEVR = Familial exudative vitreoretinopathy, GA = Gyrate atrophy, LCA = Leber's congenital amaurosis, MAC = Microphthalmia, anophthalmia, coloboma, MD = macular dystrophy, OA = optic atrophy, PD = pattern dystrophy, PXE = pseudoxanthoma elasticum, RP = retinitis pigmentosa. pat = number of patients. img = number of FAF images. Feature metrics are averaged across all images per gene. Features: % = average incidence in percent, A = averge area in mm^2, C = average number of clusters, I = average pixel intensity in percentage, % <6mm = average incidence within 6mm area in percent, FD = vessel fractal dimensions, D = average vessel density, W = average vessel width, DTM = distance tortuosity mean, SCTM = squared curvature tortuosity mean, TDM = tortuosity density mean.

gene	pheno	pat	img	disc				hypo-AF					hyper-AF					ring					vessels					
				A	C	I	% <6mm	%	A	C	I	% <6mm	%	A	C	I	% <6mm	%	A	C	I	% <6mm	FD	D	W	DTM	SCTM	TDM
ABCA4	CR	873	7926	2.19	1.01	9.25%	13.74%	80.29%	19.81	1.45	11.13%	61.34%	18.04%	0.05	0.33	66.40%	48.28%	33.46%	0.57	1.58	59.62%	81.76%	1.33	0.08	184.81	4.81	61.64	0.71
ABCC6	PXE	17	268	1.53	1.03	16.85%	17.58%	69.03%	21.44	2.08	14.31%	32.63%	54.85%	0.23	1.20	62.52%	23.36%	8.21%	0.03	0.15	43.31%	38.00%	1.37	0.08	196.68	6.17	80.72	0.73
ABHD12	RP	4	44	2.50	1.00	11.17%	3.83%	77.27%	15.90	2.48	11.45%	49.64%	27.27%	0.02	0.27	35.63%	66.67%	2.27%	0.00	0.00	47.94%	100.00%	1.19	0.06	179.19	5.24	36.36	0.68
ADAMTSL4		1	12	2.27	1.00	11.05%	0.00%	25.00%	0.02	0.33	9.49%	0.00%	0.00%	0.00	0.00			16.67%	0.03	0.17	42.55%	100.00%	1.35	0.07	213.39	4.03	53.32	0.69
ADGRV1	RP	12	102	2.54	1.00	17.39%	1.46%	63.73%	4.88	1.19	17.73%	46.66%	8.82%	0.08	0.12	64.25%	86.49%	86.27%	1.09	3.35	52.19%	99.03%	1.13	0.02	182.36	8.66	140.31	0.67
AGBL5	RP	1	10	0.54	1.60	9.81%	0.00%	100.00%	9.49	4.80	2.21%	5.33%	0.00%	0.00	0.00			0.00%	0.00	0.00			1.31	0.04	206.99	8.55	91.48	0.72
AHI1	RP	6	49	2.85	1.00	10.99%	5.88%	65.31%	12.24	0.86	12.82%	53.64%	10.20%	0.01	0.06	42.02%	60.00%	42.86%	0.50	0.96	54.65%	85.91%	1.14	0.03	180.38	5.46	58.98	0.70
AIPL1	CR	2	25	2.48	1.00	9.60%	0.06%	8.00%	0.11	0.40	2.85%	2.66%	32.00%	0.03	0.24	47.47%	0.00%	80.00%	8.66	2.12	40.42%	41.64%	1.12	0.04	229.54	5.70	40.85	0.71
ALMS1	CR	1	11	2.36	1.00	13.89%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.10	0.04	186.00	5.01	67.32	0.70
AMACR	RP	2	12	1.69	1.00	18.99%	0.00%	41.67%	0.10	0.42	13.05%	77.46%	66.67%	0.10	0.67	56.90%	3.57%	25.00%	0.09	0.33	43.51%	75.00%	1.15	0.04	191.50	7.62	110.12	0.65
ARHGEF18	RP	3	39	2.34	1.00	15.63%	1.72%	46.15%	2.88	1.13	11.33%	6.43%	33.33%	0.12	0.69	41.63%	58.53%	56.41%	0.99	2.08	48.92%	48.09%	1.22	0.05	201.54	8.35	48.53	0.64
ARL3		1	10	3.00	1.00	7.28%	0.00%	40.00%	0.00	0.20	7.68%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			1.45	0.12	198.62	4.48	27.12	0.74
ARL6	RP	2	14	1.93	1.00	21.11%	22.91%	92.86%	35.47	1.43	16.59%	46.02%	50.00%	0.23	0.57	43.28%	85.71%	0.00%	0.00	0.00			0.89	0.00	123.00	25.43	1151.60	0.55
ATF6	ACHM	2	15	2.00	1.00	17.23%	0.55%	53.33%	2.88	0.53	13.46%	81.15%	46.67%	0.03	0.53	55.29%	38.45%	13.33%	0.02	0.13	29.13%	100.00%	1.28	0.06	229.27	4.11	47.41	0.75
ATXN7	CR	1	9	1.44	1.00	18.74%	0.00%	22.22%	0.14	0.78	0.50%	100.00%	55.56%	0.05	1.22	64.87%	0.00%	0.00%	0.00	0.00			1.36	0.08	243.18	10.45	149.14	0.73
BBS1	RP	31	286	2.59	1.02	10.41%	7.52%	67.48%	8.35	1.29	11.91%	56.94%	25.87%	0.15	0.38	47.26%	86.85%	32.52%	0.84	1.03	56.50%	72.71%	1.18	0.05	186.86	9.66	214.92	0.70
BBS10	RP	4	35	2.47	1.09	12.38%	30.85%	91.43%	8.64	1.37	11.18%	41.65%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.96	0.01	172.29	13.56	349.29	0.68
BBS12	RP	2	22	2.19	1.05	13.20%	16.11%	95.45%	22.14	2.45	7.56%	44.37%	27.27%	0.05	0.36	57.05%	57.80%	45.45%	0.34	0.91	42.80%	55.42%	1.22	0.04	193.66	8.94	93.01	0.74
BBS2	RP	2	14	2.96	1.00	7.20%	19.31%	100.00%	4.91	1.50	14.15%	76.73%	0.00%	0.00	0.00			57.14%	1.85	1.43	63.87%	89.38%	1.29	0.04	134.42	6.12	201.98	0.74
BBS5	RP	2	19	3.50	1.00	12.69%	3.59%	5.26%	0.00	0.05	23.42%	0.00%	31.58%	0.08	0.53	46.02%	82.37%	84.21%	0.93	3.95	47.36%	80.33%	1.38	0.08	206.60	11.55	199.06	0.76
BEST1	BEST	133	1461	1.84	1.01	11.59%	4.14%	40.45%	2.58	0.90	11.50%	59.70%	57.49%	0.73	1.09	61.18%	59.81%	57.49%	1.28	1.83	56.31%	77.22%	1.38	0.10	203.18	4.46	49.43	0.71
C1QTNF5	RP	10	73	1.85	1.00	13.85%	3.18%	78.08%	27.18	1.93	15.97%	23.12%	8.22%	0.01	0.07	59.98%	50.00%	1.37%	0.02	0.07	51.84%	100.00%	1.35	0.08	199.82	4.78	43.26	0.73
C21ORF2	RP	5	44	2.56	1.00	11.52%	0.37%	20.45%	0.76	0.25	32.97%	17.62%	0.00%	0.00	0.00			52.27%	1.00	1.23	56.98%	45.38%	1.28	0.07	191.13	4.31	52.74	0.73
C2ORF71	RP	10	85	2.38	1.01	13.39%	6.76%	96.47%	19.08	1.75	12.65%	65.48%	7.06%	0.00	0.07	55.40%	83.33%	23.53%	0.63	0.86	62.86%	62.54%	1.05	0.03	177.08	13.59	252.66	0.63
CABP4	ACHM	4	29	1.33	1.03	14.68%	3.45%	20.69%	0.01	0.79	0.03%	33.33%	17.24%	0.00	0.21	53.22%	0.00%	0.00%	0.00	0.00			1.11	0.03	224.24	2.22	20.98	0.71
CACNA1F	ACHM	30	265	2.04	1.01	14.76%	0.01%	5.66%	0.91	0.20	7.13%	42.39%	12.83%	0.01	0.15	59.85%	2.47%	3.77%	0.01	0.06	53.57%	79.82%	1.21	0.05	218.03	9.24	83.77	0.73
CACNA2D4	CR	1	16	1.06	1.00	17.29%	0.00%	100.00%	0.09	4.06	0.11%	80.36%	0.00%	0.00	0.00			0.00%	0.00	0.00			1.49	0.10	210.24	3.97	30.23	0.69
CDH23	RP	17	260	2.05	1.01	14.31%	6.45%	16.15%	0.71	0.47	10.44%	41.97%	19.62%	0.23	0.50	57.64%	34.17%	77.31%	2.46	2.73	47.34%	67.30%	1.05	0.02	198.91	7.97	177.84	0.68
CDH3	MD	3	21	1.65	1.19	15.05%	0.00%	100.00%	25.42	2.24	11.58%	48.30%	42.86%	0.82	1.43	45.35%	0.00%	28.57%	0.11	1.19	43.43%	0.00%	1.27	0.05	219.90	3.19	17.80	0.63

Gene																												
CDHR1	RP	18	144	2.48	1.04	12.55%	5.10%	80.56%	7.39	1.71	11.82%	66.14%	22.92%	0.18	0.26	49.52%	75.30%	36.81%	1.11	1.25	53.78%	70.56%	1.22	0.04	180.64	7.80	77.75	0.68
CEP290	ACH	16	166	2.22	0.99	14.25%	3.10%	19.88%	0.90	0.69	6.43%	48.94%	13.25%	0.10	0.25	62.19%	13.64%	70.48%	1.40	2.10	54.86%	80.08%	1.16	0.04	186.46	10.90	281.31	0.71
CEP78	CR	1	5	1.47	1.00	20.86%	12.22%	100.00%	37.38	3.80	22.08%	9.46%	100.00%	0.56	1.80	53.42%	18.37%	100.00%	3.94	2.00	51.21%	87.14%	1.01	0.01	213.43	3.91	40.37	0.77
CERKL	RP	22	249	2.63	1.00	12.26%	9.15%	82.33%	10.33	1.43	12.08%	51.71%	17.67%	0.02	0.21	46.03%	88.64%	29.72%	1.04	0.95	58.07%	65.30%	1.16	0.04	179.55	7.20	95.84	0.67
CHM	CHM	109	1731	1.45	1.06	20.61%	2.84%	82.61%	51.77	3.28	19.89%	20.95%	48.76%	0.26	0.83	54.55%	37.86%	5.55%	0.03	0.08	43.19%	32.21%	1.30	0.06	190.34	6.14	104.36	0.69
CLCC1	RP	1	12	2.37	1.00	22.89%	0.00%	25.00%	0.01	0.33	12.78%	0.00%	0.00%	0.00	0.00			33.33%	0.54	0.33	54.51%	100.00%	0.79	0.00	137.72	2.37	1.88	0.29
CLN3	RP	10	147	2.23	1.03	16.06%	8.51%	34.01%	1.75	1.17	13.96%	37.43%	2.72%	0.00	0.06	57.99%	25.00%	47.62%	0.52	1.97	49.10%	92.66%	1.29	0.06	217.27	7.86	143.39	0.73
CLRN1	RP	10	80	1.40	1.04	19.90%	4.06%	60.00%	9.38	1.71	15.71%	23.13%	23.75%	0.06	0.41	53.97%	63.16%	51.25%	0.97	1.44	52.49%	94.12%	1.02	0.01	143.88	15.66	221.72	0.67
CNGA1	RP	8	54	2.39	1.00	18.34%	2.16%	16.67%	2.91	0.20	20.70%	75.96%	3.70%	0.22	0.15	59.32%	21.66%	22.22%	1.32	0.89	60.53%	65.29%	1.30	0.07	206.51	7.38	89.46	0.70
CNGA3	ACHM	36	289	1.74	1.01	13.81%	14.49%	31.14%	1.48	0.96	7.06%	56.25%	7.96%	0.05	0.17	53.96%	31.76%	35.64%	0.32	0.75	50.03%	74.89%	1.24	0.05	209.19	5.17	70.94	0.70
CNGB1	RP	28	198	1.59	1.03	13.07%	1.74%	79.80%	19.98	2.03	10.08%	25.60%	46.46%	0.57	0.95	54.04%	50.81%	70.71%	3.63	2.64	54.52%	64.45%	1.17	0.03	160.01	7.17	90.08	0.68
CNGB3	ACHM	39	288	1.91	0.99	14.86%	12.72%	12.50%	0.16	0.38	6.73%	73.57%	10.42%	0.01	0.12	52.72%	63.89%	32.64%	0.20	0.63	54.64%	92.23%	1.24	0.06	205.53	6.42	67.09	0.70
COL11A1		1	8	2.64	1.00	6.77%	2.55%	100.00%	0.73	2.75	6.21%	61.71%	37.50%	0.01	0.38	34.48%	33.33%	12.50%	0.04	0.38	40.40%	100.00%	1.13	0.04	178.64	3.60	29.13	0.58
COL18A1		2	2	0.26	1.00	13.17%	0.00%	50.00%	34.50	3.00	19.81%	14.65%	50.00%	0.25	0.50	55.09%	1.23%	0.00%	0.00	0.00			1.01	0.02	205.69	2.51	5.27	0.86
COL2A1		1	8	1.71	1.38	19.62%	13.38%	100.00%	27.44	2.63	8.53%	6.64%	75.00%	0.56	0.88	63.15%	0.00%	25.00%	0.07	0.25	46.61%	27.85%	1.15	0.03	188.28	3.09	21.79	0.69
COL4A1		1	7	1.93	1.00	16.31%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.50	0.14	188.66	3.98	37.88	0.70
COL4A5		1	10	1.61	1.00	12.84%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00		100.00%	11.30	4.10	57.72%	80.63%	1.20	0.03	194.98	8.70	85.90	0.81
CRB1	LCA	47	455	1.97	1.02	14.70%	3.63%	55.16%	8.30	1.22	15.60%	40.44%	43.96%	0.41	0.89	46.39%	54.00%	43.74%	1.73	1.35	48.91%	59.21%	1.11	0.04	178.82	7.20	83.21	0.69
CRX	CR	26	236	2.11	1.00	15.62%	5.73%	70.34%	5.51	1.39	15.62%	62.69%	16.95%	0.05	0.26	50.74%	29.92%	59.32%	2.23	4.22	52.94%	65.95%	1.33	0.07	192.40	9.58	119.49	0.72
CTNNA1	MD	4	10	1.51	1.30	18.54%	0.00%	40.00%	1.50	2.20	1.60%	13.10%	60.00%	0.23	1.20	56.33%	99.44%	50.00%	0.04	0.80	56.60%	80.51%	1.42	0.09	192.93	4.01	26.94	0.71
CWC27	RP	1	1	0.30	1.00	21.28%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			0.56	0.00	80.80	3.13	1.54	0.41
CYP4V2	RP	17	106	1.18	1.06	22.53%	3.07%	86.79%	35.05	3.20	16.02%	33.68%	15.09%	0.02	0.20	49.14%	61.88%	3.77%	0.01	0.04	32.83%	50.00%	1.00	0.02	144.85	4.90	28.37	0.63
DRAM2	CR	8	70	2.46	1.00	14.67%	9.78%	90.00%	5.97	1.50	17.68%	89.28%	2.86%	0.00	0.03	29.53%	100.00%	34.29%	0.29	0.96	59.39%	73.82%	1.37	0.08	190.91	5.03	65.16	0.73
DYNC2H1	RP	1	3	3.05	1.00	33.60%	0.00%	33.33%	0.30	0.33	35.71%	100.00%	0.00%	0.00	0.00		66.67%	0.76	1.67	61.57%	100.00%	1.07	0.02	155.01	7.69	157.23	0.49
EFEMP1	Drusen	30	249	1.77	1.00	15.28%	5.98%	78.71%	5.15	1.84	14.24%	82.36%	77.91%	0.24	1.55	61.84%	79.37%	24.10%	0.18	0.66	60.03%	82.55%	1.43	0.10	208.55	4.31	39.45	0.72
EYS	RP	70	628	2.36	1.02	15.16%	2.88%	65.92%	9.55	1.64	13.27%	27.28%	23.41%	0.23	0.40	57.64%	42.90%	72.45%	2.08	2.76	52.59%	76.78%	1.16	0.03	172.31	7.39	108.29	0.69
FAM161A	RP	8	62	2.12	1.05	14.58%	14.56%	66.13%	11.60	2.02	13.90%	40.33%	19.35%	0.27	0.35	46.78%	58.46%	83.87%	1.83	2.77	51.04%	90.53%	1.10	0.02	168.97	5.66	45.07	0.65
FLVCR1	RP	4	27	1.01	0.93	16.45%	3.53%	48.15%	2.58	1.85	5.93%	41.36%	18.52%	0.15	0.37	75.14%	20.00%	74.07%	3.76	1.78	49.80%	78.55%	1.06	0.02	176.65	9.58	88.25	0.70
FZD4	FEVR	2	9	2.78	1.11	9.17%	16.13%	66.67%	2.59	1.11	9.48%	58.83%	44.44%	0.12	0.56	78.35%	0.00%	33.33%	0.02	0.56	71.29%	0.00%	1.40	0.10	211.97	4.37	35.44	0.66
GNAT2	ACHM	2	31	2.03	1.00	15.64%	0.00%	0.00%	0.00	0.00			9.68%	0.01	0.10	52.77%	0.00%	0.00%	0.00	0.00			1.35	0.08	230.33	4.50	55.07	0.73
GPR143	ALB	6	28	2.31	1.00	13.46%	0.74%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.43	0.11	209.76	5.46	61.22	0.71
GPR179	CSNB	2	12	2.71	1.00	13.40%	3.57%	50.00%	0.95	0.67	21.58%	100.00%	0.00%	0.00	0.00			50.00%	1.97	1.33	51.76%	100.00%	1.30	0.06	221.14	9.26	157.48	0.75
GRK1	CSNB	1	4	3.41	1.00	22.44%	0.00%	100.00%	2.02	1.00	31.29%	97.92%	0.00%	0.00	0.00		100.00%	1.88	2.25	54.96%	100.00%	1.28	0.04	185.11	8.14	150.90	0.76
GRM6	CSNB	5	17	1.69	1.12	14.61%	0.00%	41.18%	0.42	0.82	8.63%	9.56%	23.53%	0.04	0.24	60.87%	0.00%	11.76%	0.02	0.18	73.19%	0.00%	1.19	0.06	162.84	3.47	23.22	0.66
GUCA1A	CD	11	79	2.25	1.01	16.55%	9.69%	41.77%	2.57	0.80	17.77%	58.47%	25.32%	0.02	0.24	57.05%	65.00%	69.62%	1.14	1.89	60.80%	93.77%	1.21	0.07	175.35	4.35	34.07	0.61
GUCY2D	LCA	28	256	2.00	1.00	14.65%	6.51%	48.05%	5.25	0.86	17.50%	71.23%	17.58%	0.22	0.30	61.24%	35.99%	60.94%	1.51	2.94	53.11%	74.98%	1.29	0.07	197.87	5.41	64.41	0.72
HGSNAT	RP	11	150	2.04	1.01	19.73%	7.15%	87.33%	25.58	2.53	19.35%	23.44%	47.33%	0.61	0.89	59.42%	60.81%	76.00%	3.46	2.91	50.43%	84.38%	1.16	0.04	173.35	6.01	52.57	0.68
HPS6	ALB	1	2	1.98	1.00	10.33%	0.00%	0.00%	0.00	0.00			50.00%	0.01	0.50	60.38%	0.00%	100.00%	0.66	1.50	67.26%	91.78%	1.43	0.12	224.18	5.33	53.82	0.70
IFT140		8	74	2.45	1.01	13.92%	2.45%	72.97%	26.72	1.93	14.83%	41.25%	28.38%	0.04	0.34	51.37%	54.63%	27.03%	0.57	0.77	47.30%	63.40%	1.05	0.03	178.13	8.60	175.65	0.64
IMPDH1	RP	6	102	1.03	1.15	20.24%	1.41%	16.67%	0.74	0.49	7.60%	6.21%	70.59%	0.69	1.00	78.22%	1.37%	74.51%	5.84	1.47	43.96%	42.58%	1.10	0.03	186.45	11.70	355.53	0.72
IMPG1	RP	2	10	2.57	1.00	13.09%	10.11%	70.00%	0.63	0.60	10.29%	100.00%	30.00%	0.16	0.30	62.18%	66.67%	70.00%	0.25	1.60	61.95%	53.47%	1.41	0.10	206.75	9.02	147.19	0.72
IMPG2	RP	12	101	2.61	1.02	14.77%	3.69%	58.42%	4.78	1.06	13.69%	30.79%	9.90%	0.05	0.21	57.06%	57.45%	27.72%	0.26	0.71	44.02%	68.09%	1.13	0.03	197.91	7.92	135.19	0.68

Gene	Cat																											
INPP5E		4	27	1.88	1.04	9.15%	3.72%	37.04%	0.95	1.85	1.51%	35.60%	7.41%	0.00	0.07	42.62%	100.00%	92.59%	3.00	4.00	58.85%	80.90%	1.38	0.07	197.45	4.24	56.23	0.68
IQCB1		8	48	2.33	1.00	10.80%	18.66%	18.75%	1.36	0.27	14.41%	34.34%	14.58%	0.10	0.19	41.52%		51.81%	85.42%	3.57	3.42	38.49%	71.76%	1.19	0.04	214.53	4.42	35.61	0.71
JAG1	ODT	1	10	2.85	1.00	12.21%	52.78%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.41	0.09	195.27	6.02	179.10	0.77
KCNJ13	LCA	1	1	0.04	1.00	6.74%	0.00%	100.00%	24.14	1.00	7.38%	51.12%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.78	0.00	132.76	11.98	34.13	0.51
KCNV2	CD	24	159	2.06	1.01	12.71%	5.01%	35.85%	1.77	0.75	13.62%	84.52%	9.43%	0.01	0.08	53.98%	67.72%	52.20%	0.92	2.87	51.85%	82.53%	1.27	0.07	199.15	6.01	79.68	0.73
KIF11		1	1	1.55	1.00	16.73%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			0.83	0.00	158.06	1.13	1.25	0.67
KIZ	RP	1	2	2.77	1.00	8.86%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00		100.00%		2.97	9.50	46.16%	100.00%	1.41	0.10	108.94	8.33	73.84	0.77
KLHL7	RP	8	75	2.40	0.99	9.63%	0.22%	70.67%	13.00	1.92	13.58%	30.31%	24.00%	0.29	0.32	55.77%	93.11%	84.00%	3.32	5.05	49.44%	89.12%	1.08	0.02	155.27	4.88	46.52	0.68
LAMA1		3	64	1.82	1.03	15.16%	11.46%	73.44%	14.25	1.59	11.84%	3.88%	62.50%	0.68	1.02	51.90%	29.27%	68.75%	1.70	3.20	49.59%	34.35%	1.28	0.05	230.37	2.95	26.37	0.79
LCA3	LCA	1	2	0.21	1.00	8.14%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00		100.00%		1.05	4.00	23.52%	90.24%	0.89	0.00	173.64	2.87	41.26	0.69
LCA5	LCA	3	22	1.68	0.95	12.37%	1.64%	77.27%	21.91	0.95	12.25%	36.27%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.91	0.01	163.08	2.27	11.30	0.61
LHON	OA	3	9	1.93	1.00	16.85%	11.09%	22.22%	0.26	0.44	13.18%	0.00%	22.22%	0.01	0.22	30.78%	0.00%	22.22%	0.05	0.44	30.19%	0.00%	1.29	0.07	200.32	11.21	156.87	0.75
LRAT		1	6	1.27	1.00	47.65%	0.00%	0.00%	0.00	0.00			83.33%	0.18	1.00	65.92%	38.33%	50.00%	0.10	0.50	67.11%	67.84%	0.93	0.01	198.61	64.14	3810.75	0.84
MAK	RP	1	6	1.97	1.00	22.73%	0.00%	100.00%	2.96	3.17	15.83%	19.65%						50.00%	0.48	2.17	47.06%	97.53%	1.12	0.01	163.64	8.17	284.51	0.70
MERTK		16	199	2.32	1.01	16.10%	2.09%	50.25%	4.65	0.78	13.72%	67.63%	40.70%	0.09	0.58	50.57%	74.20%	49.25%	0.26	1.11	52.78%	86.12%	1.12	0.03	203.52	7.47	143.86	0.70
MFRP	RP	5	95	1.52	1.05	9.39%	16.23%	63.16%	4.52	1.24	5.81%	12.76%	49.47%	0.14	0.84	66.66%	11.94%	10.53%	0.11	0.38	35.89%	90.00%	1.45	0.12	219.12	4.58	59.51	0.72
MFSD8		12	132	2.50	1.02	16.29%	11.16%	90.91%	9.35	1.48	16.31%	77.20%	4.55%	0.00	0.06	53.64%	83.33%	29.55%	0.71	1.06	53.56%	79.47%	1.16	0.05	180.60	4.76	37.14	0.68
MKKS	RP	2	41	2.79	1.07	10.91%	23.12%	73.17%	0.82	1.10	13.35%	61.34%	58.54%	0.13	0.59	41.18%	57.57%	0.00%	0.00	0.00			0.99	0.01	199.05	17.37	849.58	0.71
MT-ATP6	RP	2	30	1.87	1.00	8.18%	0.02%	100.00%	14.49	2.27	11.39%	38.65%	76.67%	0.64	1.57	38.90%	71.42%	50.00%	0.25	0.57	37.80%	83.24%	0.90	0.01	142.39	15.17	584.20	0.73
MT-ND1		2	11	1.94	1.00	22.93%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.40	0.10	204.03	6.87	77.56	0.74
MT-TL1		18	121	2.45	1.00	15.52%	9.29%	99.17%	27.19	1.83	17.96%	60.58%	8.26%	0.01	0.09	72.61%	53.87%	2.48%	0.03	0.05	57.33%	41.27%	1.38	0.08	200.53	4.72	56.76	0.73
MYO7A	RP	49	489	2.07	0.99	15.77%	2.33%	42.33%	2.37	0.95	18.00%	32.93%	28.02%	0.41	0.97	53.69%	21.82%	73.62%	3.24	3.26	47.00%	57.83%	1.09	0.03	182.09	11.00	296.77	0.70
NDP	FEVR	1	4	2.60	1.00	6.09%	25.00%	50.00%	10.17	2.50	6.10%	0.00%	50.00%	0.05	0.50	68.53%	50.00%	0.00%	0.00	0.00			1.31	0.09	193.26	4.32	60.09	0.72
NEK1	RP	1	2	2.26	1.00	9.98%	0.00%	0.00%	0.00	0.00			50.00%	0.01	0.50	50.11%	0.00%	0.00%	0.00	0.00			1.44	0.11	213.59	2.76	17.96	0.72
NHS	MAC	1	5	2.52	1.00	13.94%	2.33%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.39	0.09	214.62	5.06	34.29	0.75
NMNAT1	LCA	1	6	2.15	1.00	22.95%	0.00%	100.00%	6.93	2.33	25.50%	11.76%	100.00%	2.91	2.67	70.54%	0.00%	100.00%	2.20	2.67	60.04%	11.90%	1.16	0.04	208.21	9.04	31.13	0.83
NPHP4		1	9	2.20	1.00	19.19%	0.00%	0.00%	0.00	0.00			55.56%	0.04	0.44	64.42%	0.00%	100.00%	6.05	1.67	57.05%	60.07%	1.24	0.04	225.33	7.56	204.69	0.70
NR2E3		27	384	1.94	1.02	10.88%	7.39%	31.51%	1.42	0.76	10.23%	12.89%	21.35%	0.37	0.50	56.46%	17.86%	39.58%	1.72	1.40	52.18%	24.68%	1.32	0.08	202.83	5.85	77.48	0.72
NR2F1	OA	1	5	1.87	1.00	11.70%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.32	0.08	209.49	15.72	110.93	0.65
NRL	RP	6	26	2.01	1.04	16.78%	8.27%	69.23%	8.00	2.19	13.37%	41.91%	26.92%	0.12	0.31	56.64%	88.18%	69.23%	2.80	1.85	48.05%	90.56%	1.16	0.03	201.74	8.27	54.69	0.68
NYX	CSNB	7	46	2.39	1.00	13.23%	1.03%	4.35%	0.20	0.26	2.38%	57.84%	4.35%	0.00	0.04	65.70%	0.00%	13.04%	0.36	0.28	59.71%	40.38%	1.22	0.07	202.06	5.87	44.63	0.72
OAT	GA	8	143	1.93	1.14	11.96%	1.96%	74.83%	47.65	2.17	9.98%	12.27%	61.54%	0.22	1.01	51.11%	20.33%	18.88%	0.12	0.31	35.56%	12.35%	1.13	0.03	191.12	7.10	85.81	0.67
OCA1	ALB	1	1	0.97	1.00	10.58%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			0.93	0.02	189.77	2.07	30.82	0.52
OCA2	ALB	8	79	1.64	1.01	24.24%	1.33%	7.59%	0.99	0.16	27.76%	3.03%	3.80%	0.00	0.04	75.84%	0.00%	0.00%	0.00	0.00			1.05	0.02	202.58	6.34	42.42	0.65
OPA1	OA	26	127	1.89	1.00	17.48%	5.24%	1.57%	0.01	0.02	12.34%	0.00%	16.54%	0.01	0.30	57.81%	8.61%	0.79%	0.00	0.01	68.94%	0.00%	1.40	0.10	210.36	5.59	71.17	0.73
OPN1LW		1	2	2.17	1.00	10.64%	0.00%	0.00%	0.00	0.00			50.00%	0.25	1.00	55.91%	0.00%	0.00%	0.00	0.00			1.46	0.12	181.40	3.60	39.21	0.74
PAX2		1	10	2.06	1.00	30.18%	0.00%	10.00%	1.97	0.10	24.27%	23.62%	10.00%	0.01	0.10	77.32%	0.00%	10.00%	0.00	0.10	74.14%	0.00%	1.12	0.03	207.97	4.36	28.24	0.53
PAX6		7	27	1.78	1.00	15.30%	0.00%	0.00%	0.00	0.00			7.41%	0.00	0.00	70.69%		0.00%	0.00	0.00			1.08	0.04	195.64	7.60	43.89	0.69
PCDH15	RP	8	103	2.17	1.04	14.76%	0.00%	74.76%	9.68	2.16	10.91%	24.24%	33.01%	0.15	0.47	56.83%	62.04%	87.38%	4.50	3.33	51.23%	65.06%	1.12	0.02	162.39	6.92	98.70	0.67
PDE6A	RP	13	108	2.61	1.02	16.48%	0.02%	52.78%	12.80	1.38	17.06%	23.69%	35.19%	0.19	0.51	49.45%	67.39%	65.74%	2.14	3.56	49.36%	95.54%	1.09	0.03	197.01	10.30	197.25	0.71
PDE6B	RP,CSNB	24	272	2.62	1.01	14.75%	3.35%	52.21%	4.48	0.93	17.05%	49.30%	21.32%	0.08	0.28	55.09%	56.89%	86.03%	3.37	4.06	47.35%	86.55%	1.12	0.03	181.70	7.22	113.36	0.71
PDE6C		7	66	2.17	1.00	14.32%	6.53%	40.91%	1.21	0.52	11.44%	79.35%	4.55%	0.00	0.03	47.63%	100.00%	45.45%	1.25	2.65	45.12%	68.89%	1.14	0.03	209.81	10.06	141.35	0.66

Gene	Cat	n1	n2																									
PDE6G	RP	2	17	1.93	1.00	14.42%	0.00%	94.12%	24.60	2.06	8.28%	2.59%	5.88%	0.06	0.06	42.42%	100.00%	58.82%	0.89	0.88	52.89%	100.00%	0.93	0.01	146.18	8.57	97.44	0.63
PEX1		1	1	1.12	1.00	16.41%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			0.96	0.01	169.76	5.39	20.10	0.79
PHYH	RP	3	23	1.69	1.04	16.25%	7.65%	73.91%	15.09	2.00	16.61%	49.14%	17.39%	0.13	0.22	48.62%	70.92%	56.52%	2.32	1.57	52.79%	55.29%	1.02	0.02	211.91	19.76	587.68	0.70
PMM2		1	8	3.17	1.00	9.85%	0.00%	50.00%	0.51	0.50	16.16%	100.00%	0.00%	0.00	0.00			50.00%	1.49	1.50	43.02%	100.00%	1.32	0.07	189.42	3.90	34.53	0.72
PNPLA6		4	44	1.09	0.95	17.85%	37.45%	90.91%	76.83	2.05	16.65%	41.66%	11.36%	0.03	0.14	32.67%	60.43%	20.45%	1.52	3.11	45.99%	77.18%	1.11	0.03	212.07	12.77	169.49	0.70
POC1B	CR	4	39	2.01	1.00	15.65%	6.44%	12.82%	0.80	0.13	24.00%	99.92%	2.56%	0.00	0.03	83.77%	0.00%	7.69%	0.17	0.41	58.99%	71.49%	1.33	0.08	213.24	8.42	149.54	0.73
PROM1	CR	52	461	2.31	1.01	12.44%	6.86%	80.69%	12.22	1.73	12.48%	72.05%	20.61%	0.03	0.25	52.15%	72.15%	34.49%	0.91	2.02	53.90%	82.54%	1.26	0.06	180.39	6.32	113.25	0.72
PRPF3	RP	6	68	2.19	0.99	19.71%	4.63%	73.53%	3.76	1.07	13.84%	67.07%	45.59%	0.61	0.50	56.20%	86.15%	76.47%	3.17	2.24	46.35%	72.56%	1.03	0.02	181.57	9.51	132.07	0.72
PRPF31	RP	57	592	2.20	1.03	15.53%	1.24%	48.14%	6.78	1.56	11.97%	41.34%	18.75%	0.12	0.34	45.89%	68.33%	64.02%	2.17	2.85	52.53%	86.92%	1.21	0.04	178.26	7.11	146.19	0.70
PRPF6	RP	4	13	2.41	1.00	21.36%	13.61%	76.92%	7.04	1.15	19.73%	16.43%	30.77%	0.11	0.69	46.10%	81.05%	53.85%	4.38	0.54	44.78%	40.87%	1.20	0.04	189.15	6.06	67.83	0.72
PRPF8	RP	18	172	2.33	1.02	14.57%	2.46%	29.65%	1.73	0.65	10.35%	26.14%	13.95%	0.02	0.15	62.66%	44.31%	86.05%	2.78	2.72	52.30%	88.57%	1.12	0.03	167.83	10.67	145.07	0.69
PRPH2	CR	148	1218	2.05	1.01	12.34%	4.47%	68.72%	10.28	1.89	10.10%	62.00%	36.37%	0.07	0.58	59.10%	77.08%	26.27%	0.69	0.85	55.77%	69.43%	1.36	0.08	184.62	4.76	52.09	0.71
PRSS56	MAC	1	2	1.98	1.00	22.54%	11.52%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.42	0.13	262.82	2.82	18.30	0.72
PYGM	PD	3	14	2.21	1.00	17.53%	0.00%	21.43%	3.02	0.21	10.63%	82.58%	71.43%	0.09	1.14	62.44%	81.32%	0.00%	0.00	0.00			1.42	0.11	145.64	3.71	29.34	0.74
RAB28	CR	1	32	2.63	1.00	11.14%	0.00%	0.00%	0.00	0.00			46.88%	0.13	0.47	72.50%	100.00%	100.00%	1.32	1.41	69.75%	100.00%	1.32	0.06	218.28	4.60	118.18	0.69
RAX2		3	40	2.58	1.00	20.76%	19.89%	90.00%	6.76	1.05	22.01%	52.94%	7.50%	0.02	0.10	62.30%	34.82%	32.50%	0.07	0.63	48.86%	77.67%	1.26	0.05	208.85	10.22	118.59	0.70
RBP3	RP	2	17	2.06	1.00	15.14%	1.73%	70.59%	7.06	1.35	13.79%	34.18%	52.94%	0.67	1.53	45.94%	22.22%	11.76%	0.01	0.12	51.40%	50.00%	1.05	0.02	164.58	8.97	70.22	0.67
RDH12	LCA	29	279	1.92	1.01	18.02%	11.77%	58.06%	22.35	1.10	19.00%	37.32%	33.69%	0.37	0.52	49.05%	22.06%	34.05%	1.51	2.52	57.88%	84.76%	0.99	0.03	179.48	3.48	20.59	0.72
RDH5		9	76	1.21	1.04	27.31%	0.00%	22.37%	2.90	0.39	16.27%	17.58%	23.68%	0.14	0.38	44.14%	8.08%	19.74%	0.25	0.58	41.17%	40.00%	1.01	0.02	193.80	5.48	69.47	0.70
REEP6	RP	3	43	2.45	1.02	18.13%	0.00%	44.19%	1.78	1.02	15.53%	15.83%	9.30%	0.01	0.12	61.28%	50.00%	90.70%	2.38	5.53	57.55%	97.92%	1.18	0.02	184.26	11.54	415.76	0.75
RGR	RP	1	10	1.95	1.00	31.35%	0.00%	100.00%	111.10	3.50	33.96%	17.84%	0.00%	0.00	0.00			0.00%	0.00	0.00			1.14	0.02	218.95	6.17	66.37	0.73
RHO	RP	107	968	2.17	1.03	15.53%	1.53%	61.88%	9.74	1.72	13.64%	34.76%	18.49%	0.11	0.24	52.95%	55.98%	70.56%	2.25	2.99	53.62%	82.80%	1.22	0.04	175.72	6.49	86.13	0.69
RLBP1		6	42	1.62	1.00	19.39%	0.30%	69.05%	7.51	1.90	16.27%	27.24%	33.33%	0.04	0.38	45.37%	63.77%	9.52%	0.04	0.12	40.72%	100.00%	1.11	0.03	209.37	19.39	327.98	0.69
RP1	RP	115	951	2.19	1.01	13.69%	5.55%	62.99%	9.32	1.76	13.07%	40.06%	19.14%	0.18	0.27	55.90%	66.70%	64.98%	2.03	2.98	54.56%	74.81%	1.23	0.05	174.37	6.93	139.44	0.70
RP1L1		18	169	1.82	1.04	16.11%	7.92%	48.52%	3.52	1.76	4.43%	29.00%	8.28%	0.00	0.06	56.38%	44.95%	30.18%	0.79	1.15	54.11%	79.65%	1.30	0.08	200.64	4.74	46.77	0.66
RP2	RP	28	332	2.48	1.05	9.87%	13.25%	47.59%	3.10	1.19	10.55%	48.28%	6.93%	0.02	0.08	54.74%	84.40%	12.95%	0.26	0.38	58.97%	67.79%	1.19	0.04	181.19	6.83	109.26	0.69
RP9	RP	9	103	2.10	1.02	15.49%	1.94%	40.78%	3.50	1.51	11.09%	13.82%	7.77%	0.01	0.07	48.98%	50.03%	67.96%	3.34	1.70	54.39%	71.25%	1.24	0.05	171.05	6.24	121.52	0.69
RPE65	LCA	18	82	1.15	1.06	19.28%	7.57%	52.44%	40.13	2.65	15.03%	29.14%	37.80%	0.24	0.65	56.35%	61.75%	4.88%	0.19	0.05	43.10%	97.60%	0.97	0.02	164.35	6.64	110.77	0.65
RPGR	RP	161	1429	2.31	1.01	13.72%	3.67%	54.23%	7.78	1.27	14.36%	36.54%	22.60%	0.13	0.31	54.42%	58.64%	61.30%	2.13	2.09	55.94%	81.99%	1.19	0.04	182.93	8.03	126.10	0.70
RPGRIP1		7	93	2.73	1.00	13.28%	0.00%	4.30%	0.00	0.04	7.57%	25.00%	15.05%	0.02	0.15	51.47%	0.00%	70.97%	1.08	3.42	43.87%	85.01%	1.16	0.03	206.41	9.28	284.07	0.71
RS1	RS	100	1186	1.93	1.00	11.86%	3.50%	26.81%	2.41	0.58	10.68%	36.67%	24.79%	0.10	0.37	44.28%	73.17%	16.95%	0.35	0.59	53.00%	66.36%	1.34	0.09	207.50	5.45	62.27	0.72
SAG		4	47	2.99	1.04	13.28%	0.00%	31.91%	1.19	0.53	20.98%	63.99%	0.00%	0.00	0.00		14.89%		0.42	0.47	54.36%	89.84%	1.20	0.04	228.97	9.02	87.09	0.69
SDCCAG8		1	11	3.19	1.00	9.09%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			100.00%	1.43	3.91	51.65%	100.00%	1.40	0.08	182.97	7.54	83.15	0.76
SGSH	RP	1	2	3.23	1.00	6.49%	0.00%	100.00%	2.46	2.50	6.39%	0.15%	0.00%	0.00	0.00			100.00%	1.38	3.00	40.38%	100.00%	1.32	0.05	188.58	6.61	32.76	0.73
SLC24A1	CSNB	1	4	2.67	1.00	13.92%	0.00%	0.00%	0.00	0.00			75.00%	0.92	3.75	67.49%	0.00%	75.00%	1.77	1.75	50.43%	0.00%	1.46	0.11	179.34	4.31	51.46	0.73
SLC24A5	ALB	1	5	1.75	1.00	13.56%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.36	0.10	242.22	10.66	162.99	0.76
SLC25A46	OA	1	4	2.15	1.00	17.71%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.44	0.11	195.15	6.97	144.31	0.71
SNRNP200	RP	12	122	2.26	1.00	19.33%	0.20%	73.77%	18.05	2.05	15.78%	29.08%	30.33%	0.21	0.52	51.82%	69.42%	74.59%	2.13	3.57	49.38%	96.55%	1.13	0.03	166.44	6.64	88.10	0.69
SPATA7		2	20	2.54	1.15	13.78%	4.94%	5.00%	0.13	0.10	28.36%	0.00%	35.00%	0.05	0.35	62.23%	13.51%	90.00%	1.83	3.60	40.23%	90.97%	1.14	0.03	197.80	8.37	98.86	0.70
SSBP1	OA	3	35	1.38	1.00	16.74%	18.76%	77.14%	0.62	2.49	8.56%	49.16%	20.00%	0.01	0.26	76.85%	0.00%	40.00%	1.41	1.86	54.33%	69.36%	1.20	0.04	165.92	5.26	92.93	0.73
TIMP3	PD	36	322	1.71	1.01	17.51%	9.49%	62.11%	16.35	1.84	15.26%	46.54%	30.75%	0.14	0.51	58.46%	32.56%	27.02%	0.47	1.00	55.24%	35.32%	1.39	0.09	198.27	4.99	71.86	0.71
TOPORS	RP	6	83	2.16	0.99	13.72%	0.00%	75.90%	2.58	1.88	17.39%	80.33%	4.82%	0.01	0.05	70.07%	25.00%	93.98%	3.05	4.57	56.99%	81.22%	1.29	0.06	187.25	6.93	80.81	0.71

TRNT1	RP	1	10	2.62	1.00	15.62%	0.00%	10.00%	0.00	0.00	13.96%	0.00%	0.00%	0.00	0.00			100.00%	5.69	3.60	70.63%	94.80%	1.15	0.02	184.94	10.53	269.64	0.68
TRPM1	CSNB	6	27	2.65	1.00	14.22%	0.67%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.24	0.06	207.28	7.28	63.60	0.66
TSPAN12	FEVR	1	1	2.16	1.00	9.87%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.47	0.13	205.51	4.79	64.06	0.71
TTLL5	CD	8	56	2.34	1.00	14.86%	1.59%	85.71%	3.36	1.68	17.98%	95.01%	30.36%	0.03	0.27	37.89%	100.00%	100.00%	3.07	5.32	50.65%	88.34%	1.32	0.06	213.57	8.00	121.73	0.76
TULP1		16	165	2.57	1.05	13.77%	2.78%	26.06%	0.53	0.41	15.25%	63.18%	21.82%	0.07	0.40	52.38%	27.71%	78.18%	2.56	2.96	47.46%	75.10%	1.15	0.04	199.61	12.24	251.64	0.70
TYR	ALB	12	91	1.63	1.00	12.26%	12.36%	3.30%	0.01	0.14	17.37%	16.77%	9.89%	0.01	0.20	63.87%	26.92%	0.00%	0.00	0.00			1.37	0.09	217.99	5.12	69.35	0.72
TYRP1	ALB	1	4	1.87	1.00	12.90%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.46	0.13	208.11	3.89	32.71	0.73
USH1C	RP	14	99	2.05	1.01	19.20%	2.54%	66.67%	7.01	1.63	11.29%	34.47%	29.29%	0.60	0.56	52.39%	41.64%	46.46%	1.83	1.59	46.45%	62.73%	1.01	0.02	167.35	14.95	516.55	0.67
USH1G	RP	2	12	1.89	1.00	13.40%	11.93%	33.33%	0.20	0.42	9.90%	0.00%	50.00%	0.33	1.08	56.63%	0.00%	58.33%	2.89	5.00	58.58%	1.79%	1.23	0.04	234.70	8.28	94.58	0.73
USH2A	RP	306	2858	2.17	1.02	15.63%	2.32%	61.30%	8.47	1.76	12.99%	36.45%	19.84%	0.15	0.31	53.46%	66.47%	72.08%	1.98	3.20	53.47%	87.51%	1.17	0.03	170.22	7.26	101.60	0.69
USH2C	RP	5	59	1.69	0.98	16.12%	3.42%	88.14%	10.99	2.12	11.67%	20.83%	32.20%	0.24	0.47	58.05%	90.79%	79.66%	2.09	2.98	52.11%	88.24%	1.07	0.02	156.45	6.12	82.23	0.70
VHL	VHL	1	2	2.78	1.00	20.14%	0.00%	0.00%	0.00	0.00			0.00%	0.00	0.00			0.00%	0.00	0.00			1.40	0.10	223.00	6.09	43.62	0.71
VPS13B	RP	3	37	2.10	1.00	25.51%	0.00%	48.65%	1.62	0.57	19.57%	85.24%	18.92%	0.04	0.22	43.57%	4.28%	70.27%	1.74	1.30	49.23%	94.07%	0.85	0.01	172.54	9.77	192.76	0.76
WDR19	RP	2	27	2.57	1.00	12.46%	0.00%	22.22%	2.93	0.41	14.56%	92.55%	11.11%	0.00	0.11	30.38%	92.59%	96.30%	1.55	2.37	57.59%	20.26%	1.37	0.07	162.48	3.79	22.94	0.75
WFS1	DR	4	21	1.87	1.00	24.03%	1.16%	0.00%	0.00	0.00			19.05%	0.01	1.10	62.50%	21.98%	0.00%	0.00	0.00			1.40	0.10	208.53	4.40	52.44	0.74

Supplementary Table 5: All vessel metrics across genes. Definitions of metrics are given in **Supplementary Table 5**. The table cells have been shaded with lower values in red, intermediate values in white and larger values in green.

gene	Fractal Dimension	Vessel Density	Average Width	Distance Tortuosity Mean	Squared Curvature Tortuosity Mean	Tortuosity Density Mean
ABCA4	1.33	7.65%	184.81	4.81	61.6	0.71
ABCC6	1.37	8.07%	196.68	6.17	80.7	0.73
BBS1	1.18	4.56%	186.86	9.66	214.9	0.7
BEST1	1.38	9.62%	203.18	4.46	49.4	0.71
CACNA1F	1.21	5.35%	218.03	9.24	83.8	0.73
CDH23	1.05	2.46%	198.91	7.97	177.8	0.68
CERKL	1.16	3.51%	179.55	7.2	95.8	0.67
CHM	1.3	6.20%	190.34	6.14	104.4	0.69
CNGA3	1.24	5.36%	209.19	5.17	70.9	0.7
CNGB3	1.24	5.92%	205.53	6.42	67.1	0.7
CRB1	1.11	4.27%	178.82	7.2	83.2	0.69
CRX	1.33	7.30%	192.4	9.58	119.5	0.72
EFEMP1	1.43	10.06%	208.55	4.31	39.4	0.72
EYS	1.16	3.07%	172.31	7.39	108.3	0.69
GUCY2D	1.29	6.91%	197.87	5.41	64.4	0.72
MYO7A	1.09	2.70%	182.09	11	296.8	0.7
NR2E3	1.32	8.33%	202.83	5.85	77.5	0.72
PDE6B	1.12	3.00%	181.7	7.22	113.4	0.71
PROM1	1.26	6.10%	179.6	6.5	116.9	0.72
PRPF31	1.21	4.10%	178.26	7.11	146.2	0.7
PRPH2	1.36	8.00%	184.62	4.76	52.1	0.71
RDH12	0.99	2.93%	179.48	3.48	20.6	0.72
RHO	1.22	4.47%	175.72	6.49	86.1	0.69
RP1	1.23	4.59%	174.37	6.93	139.4	0.7
RP2	1.19	3.65%	181.19	6.83	109.3	0.69
RPE65	0.97	2.04%	164.35	6.64	110.8	0.65
RPGR	1.19	4.06%	182.93	8.03	126.1	0.7
RS1	1.34	8.69%	207.5	5.45	62.3	0.72
TIMP3	1.39	9.15%	198.27	4.99	71.9	0.71
USH2A	1.17	3.42%	170.22	7.26	101.6	0.69
All	**1.25**	**5.75%**	**186.52**	**6.45**	**98**	**0.7**

Supplementary Table 6: Average increase in hypo-AF area stratified by ABCA4 variant severity. ABCA4 patients are grouped based on the severity of their genetic variants as proposed by Cornelis et al. 2022 into groups A, B and C [20].

ABCA4 severity classification	Number of Patients	Variant combination	Average increase in hypo-AF area per year (mm^2)
A	69	Severe/Severe	3.11
B	75	Intermediate/Intermediate or Severe/Intermediate	1.59
C	184	Mild/*	0.87

Supplementary Figure 3: Rate of progression of hypo-AF in mm^2 per year for patients in the three severity classification groups of *ABCA4*. Note that Group A has a higher mean rate of progression than groups B and C, as it corresponds to the group with the highest severity. Error bars denote standard error.

Supplementary Figure 4: Comparison of the mean per-patient extent of macular ring present for patients with different variants (i.e. patients with at least one copy of the given variant) in *ABCA4*. Axes are truncated to exclude 99th percentile outliers. Most variants of *ABCA4* are not associated with a macular ring of raised AF, apart from p.(Gly1961Glu) which we see reflected in the different distributions of ring area in our data.

Supplementary Figure 5: hypo-AF area within 1.5mm of the fovea compared to LogMAR best corrected visual acuity (BCVA) where higher values corresponds to poorer acuity. Axes rescaled to 90th pct of data for legibility. Each circle represents a single patient with mean value across images. Least-squares regression line in red (β=0.083, p<0.001). Mean values for select genes are indicated by red crosses. Comparing hypo-AF

area within 1.5mm of the fovea and LogMAR best corrected visual acuity (BCVA) showed a positive statistical association (β=0.083, p<0.001). However, some genes demonstrated a different relationship from the main trend. For example, in *ABCA4* a worse BCVA was observed than might be expected from hypo-AF coverage, likely because *ABCA4*-associated retinopathy usually initially affects the fovea/central macula. By contrast, *CHM* typically exhibits a spared foveal island despite having significant areas of atrophy, thus accounting for the relatively preserved BCVA.

Supplementary Figure 6: Example showing how vessel tree segmentation improves cross-modality image registration. First row shows the individual and overlaid images, and second rows shows corresponding segmented vessel masks. For the overlaid images, the IR image is rendered in red, while the FAF image is rendered in green, enabling overlap to be assessed by looking at the correspondence between the two-colour channels. Vessel trees were extracted using AIRDetect for both the IR and the FAF image. Results of automatic registration directly on the raw images (scans column) and registration on the vessel trees (vessels column) are shown. In both cases this registration was performed using the SimpleElastix package. As shown by the final column, registering using vessel trees results in better overlap than registering using images alone.

Supplementary Figure 7: 55-degree FAF image with 0.5mm, 1.5mm, and 3mm radial distances shown (corresponding to 1mm, 3mm, and 6mm diameter ETDRS regions), and scale bar with 1mm gradations.

References

1. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open 2014;4:e004015. Available at: http://bmjopen.bmj.com/content/4/2/e004015 [Accessed December 4, 2017].

2. Pontikos N, Arno G, Jurkute N, et al. Genetic Basis of Inherited Retinal Disease in a Molecularly Characterized Cohort of More Than 3000 Families from the United Kingdom. Ophthalmology 2020;127:1384–1394. Available at: http://dx.doi.org/10.1016/j.ophtha.2020.04.008.

3. Georgiou M, Robson AG, Fujinami K, et al. Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes. Prog Retin Eye Res 2024;100:101244. Available at: http://dx.doi.org/10.1016/j.preteyeres.2024.101244.

4. Lee KE, Pulido JS, da Palma MM, et al. A Comprehensive Report of Intrinsically Disordered Regions in Inherited Retinal Diseases. Genes 2023;14. Available at: http://dx.doi.org/10.3390/genes14081601.

5. Daich Varela M, Esener B, Hashem SA, et al. Structural evaluation in inherited retinal diseases. Br J Ophthalmol 2021;105:1623–1631. Available at: http://dx.doi.org/10.1136/bjophthalmol-2021-319228.

6. Delori FC, Dorey CK, Staurenghi G, et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995;36:718–729. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7890502.

7. Strauss RW, Kong X, Ho A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11. JAMA Ophthalmol 2019;137:1134–1145. Available at: http://dx.doi.org/10.1001/jamaophthalmol.2019.2885.

8. Daich Varela M, Laich Y, Hashem SA, et al. Prognostication in Stargardt Disease Using Fundus Autofluorescence: Improving Patient Care. Ophthalmology 2023;130:1182–1190. Available at: http://dx.doi.org/10.1016/j.ophtha.2023.06.010.

9. Wang Y-Z, Juroch K, Chen Y, et al. Deep Learning-Facilitated Study of the Rate of Change in Photoreceptor Outer Segment Metrics in RPGR-Related X-Linked Retinitis Pigmentosa. Invest Ophthalmol Vis Sci 2023;64:31. Available at: http://dx.doi.org/10.1167/iovs.64.14.31.

10. Charng J, Xiao D, Mehdizadeh M, et al. Deep learning segmentation of hyperautofluorescent fleck lesions in Stargardt disease. Sci Rep 2020;10:16491. Available at: http://dx.doi.org/10.1038/s41598-020-73339-y.

11. Lin S, Vermeirsch S, Pontikos N, et al. Spectrum of genetic variants in the commonest genes causing inherited retinal disease in a large molecularly characterised UK cohort. Ophthalmology Retina 2024. Available at: https://www.sciencedirect.com/science/article/pii/S2468653024000137.

12. Nguyen Q, Woof W, Kabiri N, et al. Can artificial intelligence accelerate the diagnosis of inherited retinal diseases? Protocol for a data-only retrospective cohort study (Eye2Gene). BMJ Open 2023;13:e071043. Available at: http://dx.doi.org/10.1136/bmjopen-2022-071043.

13. Dice LR. Measures of the Amount of Ecologic Association Between Species. Ecology 1945;26:297–302. Available at: http://www.jstor.org/stable/1932409.

14. Isensee F, Jaeger PF, Kohl SAA, et al. nnU-Net: a self-configuring method for deep learning-based

biomedical image segmentation. Nat Methods 2021;18:203–211. Available at:
http://dx.doi.org/10.1038/s41592-020-01008-z.

15. Valmaggia P, Friedli P, Hörmann B, et al. Feasibility of Automated Segmentation of Pigmented Choroidal Lesions in OCT Data With Deep Learning. Transl Vis Sci Technol 2022;11:25. Available at:
http://dx.doi.org/10.1167/tvst.11.9.25.

16. Zhang Q, Sampani K, Xu M, et al. AOSLO-net: A Deep Learning-Based Method for Automatic Segmentation of Retinal Microaneurysms From Adaptive Optics Scanning Laser Ophthalmoscopy Images. Transl Vis Sci Technol 2022;11:7. Available at: http://dx.doi.org/10.1167/tvst.11.8.7.

17. Zhang G, Fu DJ, Liefers B, et al. Clinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: a model development and external validation study. Lancet Digit Health 2021;3:e665–e675. Available at: http://dx.doi.org/10.1016/S2589-7500(21)00134-5.

18. Beucher S, Meyer F. The morphological approach to segmentation: The watershed transformation. In: *Mathematical Morphology in Image Processing*. CRC Press; 2018:433–481. Available at:
https://www.taylorfrancis.com/chapters/edit/10.1201/9781482277234-12/morphological-approach-segmentation-watershed-transformation-beucher-meyer.

19. Zhou Y, Wagner SK, Chia MA, et al. AutoMorph: Automated Retinal Vascular Morphology Quantification Via a Deep Learning Pipeline. Transl Vis Sci Technol 2022;11:12. Available at:
http://dx.doi.org/10.1167/tvst.11.7.12.

20. Cornelis SS, Runhart EH, Bauwens M, et al. Personalized genetic counseling for Stargardt disease: Offspring risk estimates based on variant severity. Am J Hum Genet 2022;109:498–507. Available at:
http://dx.doi.org/10.1016/j.ajhg.2022.01.008.

21. Cornelis SS, Bauwens M, Haer-Wigman L, et al. Compendium of clinical variant classification for 2,247 unique ABCA4 variants to improve genetic medicine access for Stargardt Disease. bioRxiv 2023. Available at:
https://www.medrxiv.org/content/10.1101/2023.04.24.23288782v1.

22. Fakin A, Robson AG, Fujinami K, et al. Phenotype and Progression of Retinal Degeneration Associated With Nullizigosity of ABCA4. Invest Ophthalmol Vis Sci 2016;57:4668–4678. Available at:
http://dx.doi.org/10.1167/iovs.16-19829.

23. Georgiou M, Kane T, Tanna P, et al. Prospective Cohort Study of Childhood-Onset Stargardt Disease: Fundus Autofluorescence Imaging, Progression, Comparison with Adult-Onset Disease, and Disease Symmetry. Am J Ophthalmol 2020;211:159–175. Available at: http://dx.doi.org/10.1016/j.ajo.2019.11.008.

24. Fujinami K, Zernant J, Chana RK, et al. Clinical and molecular characteristics of childhood-onset Stargardt disease. Ophthalmology 2015;122:326–334. Available at: http://dx.doi.org/10.1016/j.ophtha.2014.08.012.

25. Fujinami K, Lois N, Mukherjee R, et al. A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. Invest Ophthalmol Vis Sci 2013;54:8181–8190. Available at: http://dx.doi.org/10.1167/iovs.13-12104.

26. Khan KN, Kasilian M, Mahroo OAR, et al. Early Patterns of Macular Degeneration in ABCA4-Associated Retinopathy. Ophthalmology 2018;125:735–746. Available at: http://dx.doi.org/10.1016/j.ophtha.2017.11.020.

27. Zinkernagel MS, MacLaren RE. Recent advances and future prospects in choroideremia. Clin Ophthalmol 2015;9:2195–2200. Available at: http://dx.doi.org/10.2147/OPTH.S65732.

28. Syed R, Sundquist SM, Ratnam K, et al. High-resolution images of retinal structure in patients with choroideremia. Invest Ophthalmol Vis Sci 2013;54:950–961. Available at: http://dx.doi.org/10.1167/iovs.12-10707.

29. Fujinami K, Sergouniotis PI, Davidson AE, et al. Clinical and molecular analysis of Stargardt disease with preserved foveal structure and function. Am J Ophthalmol 2013;156:487-501.e1. Available at: http://dx.doi.org/10.1016/j.ajo.2013.05.003.

30. Shiraki K, Kohno T, Moriwaki M, Yanagihara N. Fundus autofluorescence in patients with pseudoxanthoma elasticum. Int Ophthalmol 2001;24:243–248. Available at: https://pubmed.ncbi.nlm.nih.gov/14531624/ [Accessed March 24, 2024].

31. Sparrow JR, Duncker T, Woods R, Delori FC. Quantitative Fundus Autofluorescence in Best Vitelliform Macular Dystrophy: RPE Lipofuscin is not Increased in Non-Lesion Areas of Retina. In: *Retinal Degenerative Diseases*. Springer International Publishing; 2016:285–290. Available at: http://dx.doi.org/10.1007/978-3-319-17121-0_38.

32. Shah M, Broadgate S, Shanks M, et al. Association of Clinical and Genetic Heterogeneity With BEST1 Sequence Variations. JAMA Ophthalmol 2020. Available at: http://dx.doi.org/10.1001/jamaophthalmol.2020.0666.

33. Laich Y, Georgiou M, Fujinami K, et al. Best Vitelliform Macular Dystrophy Natural History Study Report 1: Clinical Features and Genetic Findings. Ophthalmology 2024. Available at: http://dx.doi.org/10.1016/j.ophtha.2024.01.027.

34. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006;368:1795–1809. Available at: https://pubmed.ncbi.nlm.nih.gov/17113430/ [Accessed March 24, 2024].

35. Cideciyan AV, Jacobson SG. Leber congenital amaurosis (LCA): Potential for improvement of vision. Invest Ophthalmol Vis Sci 2019;60:1680. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892385/ [Accessed March 24, 2024].

36. Huang D, Heath Jeffery RC, Aung-Htut MT, et al. Stargardt disease and progress in therapeutic strategies. Ophthalmic Genet 2022;43:1–26. Available at: http://dx.doi.org/10.1080/13816810.2021.1966053.

37. Lee W, Zernant J, Nagasaki T, et al. Cis-acting modifiers in the ABCA4 locus contribute to the penetrance of the major disease-causing variant in Stargardt disease. Hum Mol Genet 2021;30:1293–1304. Available at: http://dx.doi.org/10.1093/hmg/ddab122.

38. Fujinami K, Sergouniotis PI, Davidson AE, et al. The clinical effect of homozygous ABCA4 alleles in 18 patients. Ophthalmology 2013;120:2324–2331. Available at: http://dx.doi.org/10.1016/j.ophtha.2013.04.016.

39. Fakin A, Robson AG, Chiang JP-W, et al. The Effect on Retinal Structure and Function of 15 Specific ABCA4 Mutations: A Detailed Examination of 82 Hemizygous Patients. Invest Ophthalmol Vis Sci 2016;57:5963–5973. Available at: http://dx.doi.org/10.1167/iovs.16-20446.

40. Grob S, Yonekawa Y, Eliott D. Multimodal imaging of adult-onset foveomacular vitelliform dystrophy. Saudi J Ophthalmol 2014;28:104–110. Available at: http://dx.doi.org/10.1016/j.sjopt.2014.02.001.

41. Strauss RW, Ho A, Jha A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 24-Month Period (ProgStar Report No. 17). Am J Ophthalmol 2023;250:157–170. Available at: http://dx.doi.org/10.1016/j.ajo.2023.02.003.

42. Antonelli G, Parravano M, Barbano L, et al. Multimodal Study of PRPH2 Gene-Related Retinal Phenotypes. Diagnostics (Basel) 2022;12. Available at: http://dx.doi.org/10.3390/diagnostics12081851.

43. Daich Varela M, Georgiadis A, Michaelides M. Genetic treatment for autosomal dominant inherited retinal dystrophies: approaches, challenges and targeted genotypes. Br J Ophthalmol 2023;107:1223–1230. Available at: http://dx.doi.org/10.1136/bjo-2022-321903.

44. Miere A, Le Meur T, Bitton K, et al. Deep Learning-Based Classification of Inherited Retinal Diseases

Using Fundus Autofluorescence. J Clin Med Res 2020;9. Available at: http://dx.doi.org/10.3390/jcm9103303.

45. Miere A, Capuano V, Kessler A, et al. Deep learning-based classification of retinal atrophy using fundus autofluorescence imaging. Comput Biol Med 2021;130:104198. Available at: http://dx.doi.org/10.1016/j.compbiomed.2020.104198.

46. Pontikos N, Woof W, Veturi A, et al. Eye2Gene: prediction of causal inherited retinal disease gene from multimodal imaging using deep-learning. Research Square 2022. Available at: https://www.researchsquare.com/article/rs-2110140/latest [Accessed March 11, 2024].

47. Fujinami-Yokokawa Y, Ninomiya H, Liu X, et al. Prediction of causative genes in inherited retinal disorder from fundus photography and autofluorescence imaging using deep learning techniques. British Journal of Ophthalmology 2021;105:1272–1279. Available at: http://dx.doi.org/10.1136/bjophthalmol-2020-318544.

48. Lambertus S, Lindner M, Bax NM, et al. Progression of Late-Onset Stargardt Disease. Invest Ophthalmol Vis Sci 2016;57:5186–5191. Available at: http://dx.doi.org/10.1167/iovs.16-19833.

49. Ervin A-M, Strauss RW, Ahmed MI, et al. A Workshop on Measuring the Progression of Atrophy Secondary to Stargardt Disease in the ProgStar Studies: Findings and Lessons Learned. Transl Vis Sci Technol 2019;8:16. Available at: http://dx.doi.org/10.1167/tvst.8.2.16.

50. Strauss RW, Muñoz B, Ho A, et al. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9). JAMA Ophthalmol 2017;135:1232–1241. Available at: http://dx.doi.org/10.1001/jamaophthalmol.2017.4152.

51. Heath Jeffery RC, Thompson JA, Lo J, et al. Atrophy Expansion Rates in Stargardt Disease Using Ultra-Widefield Fundus Autofluorescence. Ophthalmol Sci 2021;1:100005. Available at: http://dx.doi.org/10.1016/j.xops.2021.100005.

52. Zhao PY, Branham K, Schlegel D, et al. Automated Segmentation of Autofluorescence Lesions in Stargardt Disease. Ophthalmol Retina 2022;6:1098–1104. Available at: http://dx.doi.org/10.1016/j.oret.2022.05.020.

53. Hull S, Arno G, Plagnol V, et al. The phenotypic variability of retinal dystrophies associated with mutations in CRX, with report of a novel macular dystrophy phenotype. Invest Ophthalmol Vis Sci 2014;55:6934–6944. Available at: http://dx.doi.org/10.1167/iovs.14-14715.

54. Fujinami-Yokokawa Y, Fujinami K, Kuniyoshi K, et al. Clinical and Genetic Characteristics of 18 Patients from 13 Japanese Families with CRX-associated retinal disorder: Identification of Genotype-phenotype Association. Sci Rep 2020;10:9531. Available at: http://dx.doi.org/10.1038/s41598-020-65737-z.

55. Fujinami-Yokokawa Y, Yang L, Joo K, et al. Occult Macular Dysfunction Syndrome: Identification of Multiple Pathologies in a Clinical Spectrum of Macular Dysfunction with Normal Fundus in East Asian Patients: EAOMD Report No. 5. Genes 2023;14. Available at: http://dx.doi.org/10.3390/genes14101869.

56. Awadh Hashem S, Georgiou M, Ali RR, Michaelides M. RPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy. Cold Spring Harb Perspect Med 2023. Available at: http://dx.doi.org/10.1101/cshperspect.a041280.

57. Tee JJL, Kalitzeos A, Webster AR, et al. QUANTITATIVE ANALYSIS OF HYPERAUTOFLUORESCENT RINGS TO CHARACTERIZE THE NATURAL HISTORY AND PROGRESSION IN RPGR-ASSOCIATED RETINOPATHY. Retina 2018;38:2401–2414. Available at: http://dx.doi.org/10.1097/IAE.0000000000001871.

58. Shi C, Lee J, Wang G, et al. Assessment of image quality on color fundus retinal images using the automatic retinal image analysis. Sci Rep 2022;12:10455. Available at: http://dx.doi.org/10.1038/s41598-022-13919-2.

59. Hart WE, Goldbaum M, Côté B, et al. Measurement and classification of retinal vascular tortuosity. Int J Med Inform 1999;53:239–252. Available at: http://dx.doi.org/10.1016/s1386-5056(98)00163-4.

60. Grisan E, Foracchia M, Ruggeri A. A novel method for the automatic grading of retinal vessel tortuosity. IEEE Trans Med Imaging 2008;27:310–319. Available at: http://dx.doi.org/10.1109/TMI.2007.904657.